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Abstract
Homeopathic medicine remains widely used in Britain and around the world. The
evidence on which homeopaths base decisions about which homeopathic medicines
to prescribe comes largely from homeopathic pathogenetic trials ( HPTs).Such trials
aim to produce pathogenetic effects in healthy participants by administering repeated
doses of a homeopathic medicine. A previous systematic review  of  the quality of all
such trials performed between 1945 and 1995 found that they were generally of poor
quality.
This review looked at all HPTs’ performed up to 2009 and  found that a small
percentage of the total (3%) of such trials were of high quality. 15 met rigorous
inclusion criteria and  had methods which were likely to keep bias to a minimum.
Trials used the number and pattern of symptoms occurring in participants as
outcomes measures; these were recorded by participants in structured and
unstructured diaries and questionnaires.
 An analysis of the outcomes of such trials failed to find evidence that Homeopathic
medicines  produce pathogenetic effects in healthy adults any different to those
which occur in participants taking identical  placebo medicines.
The trials which met the inclusion criteria were generally of high methodological
quality. However, none of them used procedures to screen or select participants who
were likely to be sensitive to the particular medicine used in the trial. It is
recommended that future trials adopt such a screening process.
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Background
1.1 Homeopathy- the contemporary context
homeopathy, developed in Germany some 200 years ago (Lockie 1989), remains a
controversial but highly popular form of health care intervention worldwide. The
World Health Organisation estimate that 500 million people worldwide use
homeopathy (WHO 2005) and in the UK it is estimated that 15% of the population
use and trust it (TGI 2008). It has also always been a part of the National Health
Service, and there are currently  four homeopathic NHS hospitals receiving 55,000
referrals a year and 400 GP’s practising homeopathy and treating 200,000 patients
per year with homeopathic medicine within primary care.(British homeopathic
Association 2009).
It is important that an intervention which is so widely used, is evaluated in a robust
and scientific manner, using accepted and appropriate methods. There are valid
debates about the most appropriate methods for  evaluating the types of complex
interventions which take place in complementary therapies such as homeopathy.
(Weatherley Jones et al 2004). However, it is widely acknowledged that the most
robust research designs for evaluating all health care interventions, and those least
susceptible to various forms of bias are randomised controlled trials and systematic
reviews of such trials. (Torgerson and Torgerson 2008, Bowling and Ebrahim 2005)
It has been suggested that extraordinary claims require extraordinary standards of
evidence (Truzzi 1998).homeopathy, which involves serial dilution of substances to
ultra molecular levels, appears implausible and extraordinary. Whilst research
methods may be need to be adapted to suit the way in which the therapy is
practiced, homeopathy should certainly be subjected to at least the same standards
of evidence as any other treatment or intervention.
The mechanism of action of homeopathy remains controversial and unknown
(Bellavite and Signorini 1995) and much scepticism exists as to whether
homeopathic medicines can have any effect beyond placebo. However, a range of
research methods have been brought to bear on the study of homeopathy in recent
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years. Basic laboratory research  (see e.g. Wagner et al 1988  Bellavite et al 1991,
Jonas et al 2001, Fimiani 2000), experimental research on animals (e.g. De
Gerlache and Lans 1991, Bildet et al 1990, Conforti et al 1993, Toper et al 1990) and
numerous human clinical trials have all taken place. The Hombrex database of basic
research currently contains details of over 1300 scientific  experiments on the effects
of homeopathic preparations on biological systems. (Carstens Stiftung 2009). In
terms of clinical trials on human subjects, the most recent  meta-analysis ( Shang et
al 2005) assessed 110 placebo controlled trials.
1.2 The Importance of HPTs ( Homeopathic  Pathogenetic Trials )
The major principle of homeopathic medicine is the idea of similars that like cures
like. What this suggests in practice is that any substance which can cause symptoms
in a healthy person may cure the same symptoms in a person who is ill. 
Given that this is the major theoretical idea in homeopathy, it is crucial to test the
idea experimentally and to determine whether substances can cause pathogenetic
effects in healthy persons and the nature of any such effects.
Samuel Hahnemann, who first developed the system of homeopathic medicine,
developed a methodology for formally testing the properties of substances by testing
them on groups of healthy people. The information from these tests then suggested
the ways in which  the medicines might be used in treating patients. Hahnemann
named these trials ‘prufungs’, a term which became translated as “provings”. More
recently such tests have become known as homeopathic Pathogenetic Trials or
HPTs.(Dantas et al 2007)
The knowledge base on which homeopathy rests results from a triangulation of
information: from HPTs, from clinical practice and, where relevant, from toxicology if
the medicine is question is based on a substance which is toxic in its crude state.
( Belon 1995) Of these, HPTs remain one of the foundation stones of the practice of
homeopathic medicine. (Dominici et al 2007 Koster et al 1998)
Thus HPTs have a central role in homeopathy, both theoretically and in practice.
Most clinical decisions taken by a homeopathic practitioner about which treatment to
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use are based, to a greater or lesser degree, on information gleaned from such
HPTs. It is therefore very important to survey the knowledge base which makes up
the HPT literature and to assess the quality and reliability of such information. The
clinical practice of homeopathy can only be effective, and will only demonstrate
efficacy in research, if the information base for practice is accurate.
1.3 The Methodology of HPTs
Hahnemann developed a methodology which was quite rigorous for the time. He first
developed the idea for these trials in 1790 in correspondence with the local
authorities regarding the urgent need for medical reform (Belon 1995). “You should
choose medicines for the symptoms they produce in healthy individual’s bodies as
witnessed by repeated observation”.  He went on to test over 100 different medicines
individually in quasi –experimental studies. (De Marque 1987). To minimise bias he
recommended that only conscientious and trustworthy volunteers who were healthy
at the time of the trial should take part. Also, that medicines should be tested singly
and in pure form with close supervision of subjects throughout the duration of the
trial. Hahnemann recommended quite strict rules to control for what he believed
were important confounding variables.  His aim was to ensure a constant steady
state in which any changes caused by the medicine would be easier to detect and he
therefore recommended that the consumption of tea, coffee, alcohol, medicines,
herbs and spices and any foods which might have medicinal effects should be
avoided. Hahnemann was convinced that medicine needed to progress via clinical
experiment rather than by theoretical debate. (Dean 2004). Here he was clearly an
early champion of what later became standard procedure for all drug trials.
As Dantas et al (2006) have noted, HPTs have been methodologically innovative.
The first blinded placebo controlled “proving” took place in a Naval hospital in St
Petersburg in 1834 and a year later a double blind trial was carried out in Nuremberg
which even attempted random allocation ( Dean 2004).One of the earliest recorded
multi- centre double blind clinical trials in the history of medicine was an HPT of
Belladonna in 1906. (Bellows 1906)
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Despite these aspects of methodological rigour and innovation in some HPTs,
subsequent analysis has shown that Hahnemann’s guidelines have a number of
weaknesses many of which may have led to overestimation of pathogenetic effects
for various reasons. (Dantas 1996). These include: the absence of a control group as
standard; the use of well known friends as volunteers; the absence of blinding; close
daily supervision and recording of trivial and pre-existing symptoms ( leading to
naturally occurring and  existing symptoms being recorded as pathogenetic and  the
occurrence of Hawthorne and recall effects); the sudden prohibition of all medicinal
drugs and foodstuffs ( leading to the effects of abstinence being included as
pathogenetic symptoms); and vague definitions of healthy (leading to the inclusion of
symptoms of existing disease being included as pathogenetic ).
However, during the twentieth century the limited number of HPT’s of homeopathy
continued to follow the guidance of Hahnemann. It was only with the publication of
‘The Dynamics and Methodology of homeopathic Provings’ by Jeremy Sherr in 1994
that any significant new guidance in relation to HPTs emerged (Sherr1994).This was
the first publication which was focussed entirely on HPTs and has been very
influential for the design of many HPTs which have been conducted since that date.
Sherr described a clear methodology for the conduct of HPTs. However, his
methodology does not address a number of the weaknesses identified by Dantas.
Notably, he neglects the important role of placebo control as a comparator for the
active intervention.  Sherr identifies three major benefits of placebo in drug trials, and
admits that the first of these, distinguishing the effects of actual treatment from the
effects of the test process, is relevant. However, he dismisses the other benefits of
placebo, suggesting that  distinguishing drug effects from fluctuations in disease that
occur with time and other external factors does not apply as provings are invariably
made on healthy volunteers. This is an unwarranted assumption, since the definition
and measurement of health in participants in HPTs varies widely, and ,as will be
shown later, the most healthy of individuals do experience fluctuations in symptoms
over the course of a trial, whatever efforts are made to avoid other influences.
Subsequently various sets of guidelines were developed. One such came from the
European Committee for Homeopathy ( ECH 2004). Their drug proving group
developed very detailed protocols following a series of annual international symposia
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which had begun in 1992, and they first published guidance in 1997. In 2004 they
updated their guidelines and  based them on the structure and contents of the
Guidelines for Good Clinical Practice of the International Conference on
Harmonisation (ICH). Initially a tripartite agreement between the EU, the Unites
States and Japan, the ICH guidelines have been widely adopted worldwide and are
aimed at producing uniform standards  in relation to the design and conduct of
medical trials.(European Medicines Agency 2006). In attempting to bring guidelines
for HPTs up to the standards of the ICH, the ECH made a wide range of
recommendations, including: minimum qualifications for the principal investigator; the
definition and reporting of adverse events and serious adverse events; the need for
explicit protocols; assessment of safety; and the summary of the known risks and
benefits to participants in the trial.
Guidelines published  by Riley in 1997 also emphasised the need to address ethical
issues, to describe the origin and preparation of the homeopathic medicine in detail,
to have clear inclusion and exclusion criteria and to have very clear methods and
guidelines for symptom selection. (Riley 1997)
Walach (1997) suggested that different methodologies would be needed for different
purposes, though they might be combined. He recommended that trials aimed at
determining that homeopathic substances can produce symptoms different from
placebo should adopt placebo controlled double blind designs and to avoid carry
over effects, should be of parallel group design. In contrast trials designed to
improve practical prescribing in homeopathy and particularly those aimed at finding
new medicines would need to follow the traditional qualitative methodology which
had been used for 200 years for HPTs.
Herscu (2002) gathered together a range of historical and contemporary writings on
HPTs and developed his own guidelines. He outlined a ten step process which
included most of the steps suggested by other guidance, but also included a
recommendation to retest the provers who are most sensitive to the medicine in the
initial trial
Table 1 offers a comparison of the key published  guidance in relation to HPTs
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Table 1 Comparison of key items in published guidance on the conduct of HPTs
Author Hahne-
mann
1821
Sherr
1994
Dantas
1996
Riley
1997
Walach
1997
Herscu
2002
ECH
2004
Use of placebo NO 10-
20% 
YES NO YES 12.5% YES
Parallel group
design
NO NO YES NO YES NO NO
Randomisation
and allocation
concealment
procedures
NO NO YES NO YES NO YES
Blinding NO NO YES NO YES YES YES
Ethics approval
and informed
consent
NO NO NO YES YES YES YES
Validated
definition of
healthy
participant at
entry
NO NO YES NO NO NO NO
Procedures for
dealing with
missing data/loss
to follow up
NO NO NO YES NO NO YES
Procedures for
screening for
participants who
are sensitive to
NO NO NO NO NO YES NO
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the trial medicine
All of these guidelines have led to many recommendations for trial design. In
practice, the methodological quality of both the design and conduct of clinical and
pathogenetic trials in homeopathy remains variable though and many poor quality
trials have continued to be conducted (Linde 2001, Dantas et al 2006). It should be
noted that in this respect the situation is no different to that which pertains in other
areas of health care research.
Some HPTs have been performed which incorporate the standards which have
become the norm in medical and health related trials and have addressed the main
factors which are known to introduce bias and to lead to an overestimation of effects.
These standards include: placebo controls, clear processes of random allocation, of
allocation concealment and of  blinding of participants and researchers; as well as
explicit processes for dealing with drop outs and missing data .One purpose of this
review was to systematically review such trials, and to determine how many HPT’s
were of high methodological quality. 
1.4 Susceptibility to pathogenetic effects 
In terms of methodology, it is crucial that HPT’s are designed in ways which best
facilitate the observation and measurement of any pathogenetic effects. There is a
particular problem which is perhaps unique to HPTs which relates to susceptibility. It
is known that people respond in a range of ways to the administration of any form of
medicine. Whether healthy or sick, a person taking any form of medicine may display
a range of responses. What has been called the ‘total drug response’ will be a result
of the action of the medicine together with a range of non- specific effects and
placebo effects. (Peters 1991). One of the non specific effects relates to the
individual susceptibility.
All participants will react to sufficient doses of substance in a crude state, since any
substance if given in sufficient quantity will exert some physiological and eventually
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toxicological effects. Even water, in sufficiently large doses over a short period of
time, can lead to an acute intoxication and can lead to fatal reactions such
hyponatremia, which, for example, has caused deaths in several marathon runners
in recent years (McClatchy 2001, Almond et al 2005)
However, when substances are successively diluted in the manner used in
homeopathy they show less toxicological or direct physiological effects with
increasing dilution.  ( refs  ???????)The process involved in the preparation of
homeopathic medicines involves a series of stages of both dilution and succussion
(vigorous shaking of the dilution). Insoluble substances are first triturated with
lactose to a point at which they become soluble; other substances are diluted from
the crude state in a mixture of alcohol and water. 
Dilution usually takes place at the level of one part in ten or one part in a hundred. In
practice there are certain common levels of dilution which are used as medicines,
and these are denoted with a system of number and letters. ( see table 1.2 for details
of typical dilutions and nomenclature used in Homeopathic pharmacy)
Table 1.2 Homeopathic medicines. Levels of dilution and succession of commonly
used medicines.
Designation Level of dilution Number of stages of dilution
and succussion
1x  or  D1 One part in ten 1
6x  Or  D6 One part in ten 6
6C One part in a hundred 6
30 C One part in a hundred 30
200C One part in a hundred 200
1M One part in a hundred 1000
LM1 One part in fifty thousand 1
T
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Fig 1.1 Illustration of the stages of production of a 30C strength homeopathic medicine
This process means that increasing potencies (as they are known) contain less of
the original substance and it is thought that with each increase in potency less
people will be sensitive or susceptible to the effects of that medicine. (Herscu 2002).
Moreover, because effects will only occur in individuals with a predisposition to be
affected by the substance and the constitution and predisposition of each person
varies somewhat, it has been observed that certain symptoms will occur in some
individuals and others in different individuals. Hahnemann suggested that       “the
total picture of disease symptoms that a (homeopathic) medicine can produce
approaches completion only after multiple observations have been made on suitable
persons with various constitutions”. (Hahnemann 1921). 
The theoretical basis of homeopathy suggests that only persons who have a
particular constitutional and biological make up will be susceptible to the effects of a
specific homeopathically prepared medicine and will respond to it, and each may
respond differently. (Hahnemann 1921, Vithoulkas 1981).  According to this model of
individual susceptibility this will be  true both in clinical practice and also in HPTs.
( refs …..
13
 This means that any individual symptom may be a rare event and unlikely to be
detected using a standard RCT designs. In theory pooling data from different trials
and using meta –analysis can be helpful (if appropriate) when events rates are very
low (Deeks et al 1998), and suggests another reason for attempting a systematic
review with meta-analysis of HPTs.
 The issue of rare events and trial design is often discussed in relation to the
detection of adverse events in drug trials. However, there is a further complication
with HPT’s in that there is not a single symptom or even a small number of possible
pathogenetic effects. Kiene (1995) has pointed out that there are an enormous
number of potential symptom outcomes in a HPT and this means that statistical
detection of individual symptoms distinct from placebo and background noise is
unlikely using conventional statistics. 
One possible approach to this problem might be to take homeopathic medicines
which have already been subject to HPTs and to widespread clinical use. Outcome
measures could then focus on a limited number of key common symptoms which are
known to be linked to the medicine. This approach was taken in some of the trials
included in the current review. 
If the purpose of an HPT is to demonstrate that there is a statistically significant
difference between verum and placebo then this approach may be useful. If the
purpose is to develop a complete record of pathogenetic effects which might be
useful for clinical practice then this approach is inadequate. Kaptchuk (1996) has
concluded that “homeopathy still has no clear answer to the question or rare
symptoms versus chance symptoms in proving”. 
 It is not known what proportion of participants are likely to be sensitive to the effects
of a medicine during an HPT though the potency used will be have an impact on this.
It is thought that with increasing “potencies” (which are increasingly diluted and
succussed) homeopathic medicines will progressively target only those who are
most susceptible to their effects. For this reason most HPT’s use relatively low
potencies. Dantas et al noted that 30C was the most commonly used, followed by 6C
and 6X. The latter is the lowest potency which is generally available in homeopathic
medicines. 
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The theory clearly suggests that only a minority will respond with pathogenetic
effects to a medicine given in a homeopathic potency, though this minority may be
larger with the use of lower potencies. Many HPT‘s in the past appear to have found
that all participants displayed pathogenetic effects. (Dantas et al 2007, Herscu 2002)
As Dantas et al noted in their review this is likely to be an artefact of poor
methodological quality and to reflect non - specific effects, Hawthorne effects, and
the nature of the participants (usually enthusiastic students of homeopathy eager
and primed to expect pathogenetic effects). In their review of many HPTs these
authors noted that 84% of volunteers in verum groups  displayed symptoms, and
that in the trials of lower methodological quality all participants reported pathogenetic
effects. They give the example of two trials of the same medicine, which are of very
different methodological quality. The low quality trial (Sherr 1992) reported 5000%
more pathogenetic effects per participant than the high quality one (Schroyens
1996).
Homeopathic theory suggests that treatment should always be individualised to the
patient. It is possible to design trials of clinical homeopathic practice which allow for
individualisation of treatment and still maintain randomisation and blinding, since the
practitioner has the opportunity to interview the patient and individually select a
remedy before randomisation occurs.  If the practitioner achieves accuracy in
selecting the medicine to which each individual patient is susceptible then it is likely
to show an effect in each patient. The situation of HPTs is different.  Typically
participants taking part are volunteers who meet inclusion criteria and are willing.
There is no procedure for determining who may be susceptible to the remedy being
tested before the trial begins.  But to reiterate homeopathic theory suggests that only
persons who are susceptible will respond, whether they are healthy participants
being exposed to repeated doses of the remedy in a pathogenetic trial or whether
they are ill patients who are prescribed the remedy to treat their symptoms. In clinical
practice the Homeopath will use their skill and knowledge to match the susceptibility
of the patient to the most similar remedy. For HPTs it follows that only those who
have some susceptibility to the medicine being tested will react and  show
symptoms, and it must be important to have some kind of procedure for pre selecting
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volunteers who are sensitive enough to show pathogenetic effects from the particular
medicine used in the trial.
Shalts has summarised this problem by noting that “one of the reasons that proving
studies consistently show no difference is that the studies do not allow for people
who are not sensitive to verum. They also do not allow for the variable symptoms
that arise in every participant.” (Shalts 2002)
One of the aims of this review was to look at methods used to select and determine
the sensitivity of participants before or during trials.
1.5 Placebo and nocebo
HPTs are aimed at producing pathogenetic effects in participants. Placebo effects
can also be pathogenetic as well as beneficial. These are sometimes known as
nocebo effects (Ernst 2001).
One of the challenges for homeopathic pathogenetic trials is to establish whether the
specific signal of the medicine being tested can be distinguished from the
background noise of existing symptoms, placebo effects and other non specific
effects which may lead to the occurrence of new symptoms. In order to establish this
it is of course necessary to have carefully controlled trials with placebo groups.
Placebo effects are usually understood as therapeutic or beneficial effects occurring
after the administration of some kind of placebo intervention. 
Whilst the definition of a placebo intervention remains contested, it should strictly be
limited to those things which are imitations of an intervention with known effects, and
does not include the many non specific factors which are known to have an impact
on outcomes (Kienle and Kiene 2001). Factors which are often responsible for what
are sometimes labelled as placebo effects include: the natural course of disease;
spontaneous, irregular fluctuations in symptoms; regression to the mean, additional
treatment, giving inaccurate answers to please clinicians ( the word placebo after all
means to please); Hawthorne effects ( the tendency of people to change their
behaviour and the things that they are aware of when they are the target of special
interest);and placebo interventions which actually have some active ingredient.
(Kienle and Kiene 2001). Well conducted randomised controlled trials should control
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for these non specific factors and mean that they are spread evenly across the
intervention and placebo groups.  Any differences in outcomes should then reflect a
difference between placebo effects from the placebo intervention and real effects of
the verum intervention.
1.6 The nature size and direction of placebo effects.
When the effects of, and responses to placebo have been examined in trials it is
clear that the number of participants who demonstrate any placebo response varies,
that the pattern and direction of placebo response varies and that the response is
modulated by many factors, including expectation. For example participants who
were informed that they would definitely receive a placebo treatment showed a
different response to those who were unsure whether they would receive placebo or
an active intervention (Peters 2001). In another example, medical students who were
conditioned to expect sedative or stimulant effects, but who received pink or blue
placebo capsules, demonstrated significant placebo effects related to the expected
response (Blackwell et al 1972). Ernst suggests that patient expectation is probably
one of the strongest determinants of the placebo response (Ernst 2001).
To further illustrate the strength of this phenomenon, placebo responses can include
significant, measurable physiological changes such as airway reactivity (Kemeny et
al 2007); neurobiological responses have been measured in a range of trials and it is
clear that opiate and dopamine pathways are activated and modulated in response
to expectations (de la Fuentefernández and Stoessl 2002).
Placebo effects often seem to mimic those of active interventions and dose effect
relationships (Blackwell, Bloomfield and Buncher 1972), cumulative effects after
repeated administration and carry over effects after cessation have all been
described (Lasagna, Laties and Dohan 1950)
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Most recently researchers have suggested that differences in genotypes which affect
the enzymes which produce both dopamine and norepinephrine (both
neurotransmitters involved in reward pathways in the brain) affect responses to
placebo interventions (Leuchter 2009)
For a long period of time following a seminal paper by Beecher in 1955, there was an
assumption that placebo effects occur in a fairly constant 35% of participants in
studies. The original data on which Beecher based his figures has subsequently
been shown to be seriously flawed and work by Richardson (1994) Ernst (2001) and
others has shown that the actual figure varies between 0 % and 100% depending on
the context .Nocebo effects occur in most placebo controlled clinical trials and may
affect up to 40 % of those receiving a placebo intervention (Tangrea, Adrianza and
Helsel 1994). It was noted earlier that HPTs have some similarities with Phase 1
drug trials. Nocebo symptoms in healthy persons are commonly reported in such
trials (Sibille et al 1992). Nocebo effects take various forms and can include the
induction of pain (Benedetti et al 2006). It is known that conditioning and expectation
increase nocebo effects. (Johansen 2003) Several studies have found higher rates
of nocebo effects in female participants. (Liccardi et al 2004, Casper et al 2001).
However, to illustrate the lack of consensus about the nature and magnitude of
placebo effects. two systematic reviews by Hjobartson and Gotsche (2004)  of trials
which compared placebo interventions with no treatment, concluded that placebo
effects are very small. They found evidence of placebo effects only for patient
reported outcomes and, particularly those relating to pain.
These authors acknowledge that “our results do not exclude the possibility that other
aspects of the patient–provider interaction, or interactions between the treatment
ritual and different ways of informing patients, could have clinically useful effects.”
Because participants receiving no treatment also interact with treatment providers
there may be factors relating to relationships and contexts which lead to similar
outcomes in both groups. However, those receiving no treatment would not have the
same expectations as those receiving placebo and expectation clearly did not have
the same influence on outcomes in the trials considered for the review as in the
literature previously described.
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It seems clear that studies and reviews report wide variations in the nature and size
of placebo effects and there is not yet a clear understanding of how these operate in
trials of health interventions.
1.7 Background noise
Pathogenetic effects need to be distinguished from placebo/nocebo effects. They
also need to be distinguished from what might be called ‘background noise’.
Although HPTs are designed to use only healthy volunteers, it is clear that all people
healthy or not, experience a fluctuating level of symptoms on a day to day basis.
Kaptchuk (1996) has highlighted some studies which illustrate the size and variability
of this background noise.
 In one trial 4800 people were told that a new medicine was being tested for side
effects. Participants resided in a variety of settings, including prisons, old people’s
homes and medical professional offices. Interviews and pre-treatment questionnaires
were designed to look for pre treatment symptoms. 
Whilst the overall mean incidence of symptoms was 10%, at least half of the
symptoms occurred in 20% or more of individuals, and those in certain settings had
very high levels ( e.g. 28% of those in old people’s homes reported dizziness)
(Green 1964). In a second study 414 people who worked or studied at a university
medical centre were healthy in the sense of reporting no current illness and no
medication use in the previous 3 days.  Of this sample 81% had at least one
symptom in the previous 72 hours based on a 25 symptom adverse event
questionnaire. Kaptchuk notes that the symptom check list looked very like the
tabulated results of an HPT.
It is clear then that trials of interventions can lead to placebo effects of significant
magnitude and in significant numbers of participants. To show that an intervention is
different from placebo it must be able to produce effects of large enough magnitude
and in large enough numbers of participants to  outweigh both placebo effects which
may already be large, and existing background noise which may also be of large
magnitude, in order to reach statistical significance.
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One of the ways in which background noise can be measured and differentiated in
trials is to have a baseline or observation period before any intervention (placebo or
verum) begins. 
As discussed earlier, another method which can help to control for background noise
is to predefine symptoms which might be expected from a particular medicine and to
use outcome measures related specifically to such symptoms.
It has already been noted that  any percentage of people (from 0 to 100) may show
effects when taking placebo, that nocebo symptoms typically occur in 40% of
participants and  that any sample of even a healthy population will contain many
individuals, possibly up to 80% of the total, with existing symptoms. Also, that only a
small percentage of participants are likely to be sensitive to a particular homeopathic
medicine and to show true pathogenetic effects in HPTs. 
It follows from this that the most carefully controlled trials are likely to show little or
no difference between verum and placebo groups in HPTs in relation to the number
of individuals showing symptoms, unless the participants have already  been
screened and selected for their sensitivity before being recruited and randomised.
There may be a difference in the pattern of symptoms in the limited number of those
who do respond but not in the number of those responding.
It is notable that this factor seems to have been frequently overlooked in the design
of HPTs. A lot of attention has been paid to the selection of participants in terms of
their health status but not sufficient to issues of sensitivity. Some authors, notably
Vithoulkas (1980) and Herscu (2002) have highlighted the issue and recommended
trial designs for HPTs which incorporate a stage of selection for
sensitivity/susceptibility. 
There should be a process, perhaps involving several stages, to determine which
participants may show symptoms. Otherwise the problem exists that the percentage
of individuals who are susceptible to the substance being tested may be small and
may not exceed the percentage of responders that may be deemed to be due to
chance. 
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One way in which Homeopaths have dealt with this problem is to suggest that
verification of whether a symptom is a true symptom of the remedy or is background
noise or a placebo effect, will come from clinical practice rather than from HPTs. If a
medicine is used in an ill person and a symptom which was listed in the  HPT
disappears , then that is confirmation of the homeopathic principle of like cures like
and verification of that symptom.  However, as Kapthcuk notes, whilst this approach
makes sense in many ways, it does not help the methodology of HPT’s and only
postpones the problem (Kaptchuk 1996)
1.8 The nature of pathogenetic effects in HPTs.
homeopathic theory suggests that pathogenetic effects which occur in HPTs will
show characteristic patterns, and that these patterns are likely to be different from
placebo effects and from the type of general fluctuation in day to day symptoms
which healthy people may experience.  Each medicine is thought to produce a
characteristic or signature pattern of symptoms.
 It may be possible to predict these symptoms in advance if previous HPTs have
been carried out or if information about the particular medicine is available from
toxicology or from clinical practice.  Also, the response of the human organism to
homeopathic medicines is thought to involve a departure from homeostasis followed
by a dynamic response from the organism in an attempt to re-establish homeostasis
(Bellavite 2001, Vithoulkas 1991).Such a response may lead to intense new
symptoms, the return of old symptoms, the occurrence of symptoms in particular
parts of the body and symptoms with particular modalities. In contrast it is known that
the most frequently reported nocebo effects in trials are headache, drowsiness,
tiredness, dizziness, nausea, pain and insomnia      (Rosenwels, Brochier and Zipfel
1993)
HPT’s should use outcome measures which address and capture such patterns of
symptoms rather than simply recording the numbers of symptoms in verum and
control groups.
The forgoing discussion of susceptibility to pathogenetic effects, the nature size and
direction of placebo effects and issues of background noise, illustrates some of the
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challenges which face those designing HPTs. It remains the case that placebo
controlled trials with blinding form one of the best trial methods for reducing overall
bias. Trials which do not use comparator groups as controls to assess the level of
placebo symptoms are likely to lead to an overestimation of pathogenetic effects
from trials. On the other hand if quantitative statistical analysis of the different
responses between intervention and comparator groups  is relied upon exclusively
then an underestimation of pathogenetic effects is highly likely, particularly without a
staged approach which allows for the selection and recruitment of sensitive
volunteers for the main trial. 
1.9 Adverse events
In a systematic review of the adverse effects of homeopathy, Dantas and Rampes
(2000) found that adverse effects of homeopathic medicines in controlled clinical
trials were greater than placebo, but these were generally minor, transient and
comparable. Of course, in HPT’s the purpose of the trial is to produce pathogenetic
effects and it is important to consider when a pathogenetic effect may be considered
an adverse event. 
Pathogenetic effects which are significant may lead to participants withdrawing or
being withdrawn from trials and this may bias and complicate the collection and
analysis of data. HPT’s in which data is not collected from those who withdraw
because of adverse events related to pathogenetic effects, are likely to
underestimate overall pathogenetic effects. Under reporting of adverse events is
common in medical literature and due to widely held beliefs that homeopathic
medicines are safe, the phenomenon is thought to be greater in homeopathic
literature (Dantas and Rampes 2007).Some of the guidelines for HPTs which were
referred to earlier do explicitly state the steps that should be taken in relation to
dealing with and recording adverse events. See, for example the ECH guidelines
(ECH 1997). Again, it seems to be the case that many trials which have taken place
have not followed such guidance. Dantas et al (2007) in their review of HPTs noted
“an extremely low value of withdrawals due to severe adverse effects”. They further
noted that 85% of reports did not mention how adverse effects were managed. The
RedHot guidelines on the reporting of trials of homeopathy (Dean et al 2007) note
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that the issue of aggravation of symptoms following the administration of
homeopathic medicines should be added to category 19 (reporting of adverse
events) of the CONSORT statement on the reporting of trials.
The reporting of adverse events was one of the aspects of trials which this review
considered, as part of an assessment of the overall reporting and management of
loss to follow up.
1.10 Systematic reviews
As noted earlier systematic reviews of well conducted randomised controlled trials
are considered to be one of the best sources of evidence in health care. This is
because they help to answer focussed questions in a manner which is as free from
bias as possible. They help to ensure that a complete assessment of existing trial
literature is made using a transparent and replicable process, in a standardised way.
The rigorous methodology of systematic reviews was developed to ensure that
problems of subjectivity, selectivity and timeliness which occurred in more traditional
narrative reviews were avoided (Cullinan 2005).
Whilst there are several systematic reviews and Meta –analyses of homeopathy in
general (Kleijnen 1991, Linde 1997, Shang et al 2005) and of homeopathic treatment
for specific conditions (e.g. McCarney et al 2004, Heirs and Dean 2009) there are no
Systematic reviews of HPTs in the standard databases (DARE, Cochrane
collaboration)
There exists a systematic review of the quality of Provings (Dantas et al 2007).
entitled “A systematic review of the quality of homeopathic pathogenetic trials
published from 1945 to 1995”. 
This review has the merits of being very comprehensive and covering papers
published in six languages. An international team of 13 authors searched published
reports in English, German, Spanish, French, Portugese and Dutch from 1945 to
1995. With a focus on issues of quality, the authors assessed trials using an 87 item
checklist which included items relating to: the description of medicines, volunteers,
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ethical aspects, blinding, randomisation, and use of placebo, adverse effects,
assessments, presentation of data, and the number of claimed findings. Their
approach to quality was to score each of four key components: randomisation,
blinding, inclusion and exclusion criteria, and criteria for selection of effects. Overall
scores were then ranked in four methodological classes. The authors then discussed
differences in findings and claimed results in relation to methodological quality. They
noted that trials with low methodological rigour reported more effects per participant.
They also noted an increase in the quality of trials towards the end of the review
period, since the introduction of modern reporting guidelines such as Consort
(Altman 1996). 
In their paper they suggest that “We hope ...our study ... will stimulate a close
monitoring and comparison of methodological quality of HPTs done after 1995.”
They also note that  “the methodological quality showed a trend to improvement in
the later decades, there was a positive and significant correlation between
methodological classes and decades (rs=0,218; P =0,006 ) ”. They also note that, for
example, randomisation was first mentioned in 1961 but of the 15 reports which
mention it, nine were in the final decade of the review period.
This suggests that the amount of primary research in conducting HPTs may have
increased since 1995 and that also the quality of those  may have improved , given
that there has been much more discussion and, as noted earlier, a number of
published guidelines in relation to quality and methodology in HPT’s , as in health
research generally since the 1990’s . As Riley puts it  “Methodological rigor in
homeopathic drug proving has probably been lacking historically; however, GCP
guidelines, ethic commissions, formal protocols, and clinical trial registries are a
recent invention and one should not automatically discount the historical
homeopathic proving literature for not having used tools that were not available”.
(Riley 1997)
The Dantas et al review was a review of the quality of trials and was not designed to
synthesise data relating to outcomes. They used exploratory meta- analysis to
assess some data relating to quality, and did not make any attempt at quantification
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of results or meta-analysis. This means that there is no systematic review of HPT’s in
existence which also has a meta-analysis of quantitative outcomes.
Also, the authors had chosen a cut off date of 1995 for inclusion of studies, and it
took the international team several years to complete their findings and bring them to
publication (in 2007). Given that many of the guidelines discussed in 1.3, relating to
the conduct and methodology of HPTs, were published in 1997 or later, there is a
clear need for an updated review of HPT’s. At the outset of this review a question
remained as to how much HPT’s had changed, improved and taken on board such
guidelines since 1995 and this is a question which the review aimed to answer.
For these reasons a decision was taken to conduct a systematic review of HPTs in
order to update the work started by Dantas et al but also to revisit the whole of the
literature, using a different set of inclusion criteria with the aim of offering a greater
degree of data synthesis, and meta –analysis relating to outcomes of HPTs, if at all
possible.
Chapter Two - Methodology
2.1Formulating a research question
There is broad agreement that systematic reviews of literature relating to health care
interventions are best framed using the following components: 1.Population. 2
Intervention 3. Comparator 4.Outcome. 5 Study Design. (CRD 2009)
After an initial period of reading and development of ideas as described in Chapter
one and after consultation with supervisors the following question and components
for a review were formulated.
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Question: To determine whether the effects of homeopathic substances (ultra
molecular dilutions) on human subjects differ from the effects of placebo in
homeopathic pathogenetic trials. (HPTs)
The purpose of the review was to assess studies of the effects of homeopathic
substances on healthy participants in homeopathic pathogenetic trials, which have
some similarities with phase one drug trials. It is standard procedure to include only
healthy participants in pathogenetic trials (Wieland 1997) though few authors have
operationalised the definition of healthy or have used validated measures to assess
the state of health of participants in HPTs. The question of whether homeopathic
substances have effects when used clinically as a treatment is a different one and
the question needed to be framed in such a way as to make this clear.
2.2   Selection of studies: Assessment of relevance for inclusion in the review.
inclusion and exclusion criteria.
2.2.1 Population
Inclusion criteria
The review considered studies involving adult participants, male and female, aged
18 years or over.
2.2.2 Interventions
Inclusion criteria. The review considered studies which involved the ingestion of one
or more doses of homeopathic substances (ultra molecular dilutions).
Studies were considered which used substances  prepared according to national
homeopathic pharmacopoeias or other explicit protocols e.g. the British, French,
German, or US Homeopathic Pharmacopoeias.
Studies were considered in which substances were administered in ultra molecular
dilutions as are used in homeopathic practice.
Exclusion criteria
Studies involving mother tinctures (crude extracts) of substances were excluded.
Whilst these are used within homeopathic practice they are more properly
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considered as herbal medicines and cannot help to answer any questions about the
effects of ultra molecular dilutions. 
Studies which involved the administration of homeopathic substances by means
other than ingestion were excluded. Some studies have used olfaction as a method
of administering a substance and a number of HPTs have been published using
other methods.
2.2.3 Comparators
Inclusion criteria
Studies which reported comparing homeopathic medicines to identical placebo
medicines. 
Exclusion criteria
Studies which did not report using identical placebo medicines as a comparator.
2.2.4 Outcomes
The primary aim was to determine whether homeopathic medicines produce effects
different from placebo. Outcome measures which capture the kind of symptoms
which homeopathic theory predicts would occur were sought.  These included
symptoms in the kinds of categories expected in HPTs and pre-determined
symptoms which might be expected from the particular medicine under trial.
Guidance on the conduct of HPTs has suggested that symptoms should be recorded
in certain key categories, including new, old, changed, cured, existing, intense and
striking or uncommon symptoms (Wieland 1997, Riley 1997, ECH 1995). In relation
to pre determined symptoms, some authors define a set of true symptoms which are
those that experts deem most likely to occur as pathogenetic effects from the test
medicine. ( based on either previous HPT's or extensive clinical use). In contrast
false symptoms are those which are deemed unlikely to be due to the test medicine
and therefore are most likely to be due to placebo or random effects.
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 The number of typical symptoms recorded per participant or in the whole group are
then used as an outcome measure. Also, measures which offered some kind of
global assessment of whether a participant displayed a proving reaction or not were
sought.
Given the importance and remaining uncertainty over the nature and magnitude of
placebo effects as discussed in chapter one, a secondary  aim was to determine the
typical size of  placebo effects in HPT’s.
Inclusion Criteria
The review considered studies which reported any outcome relating to symptoms
experienced at any point in the duration of the trials. Methods for recording
symptoms include the daily completion of an unstructured diary by participants,
structured diaries and specially developed proving questionnaires.
Exclusion Criteria
Studies in which outcome were not reported by intervention group.
2.2.5 Study Designs
Inclusion Criteria
The review considered randomised controlled trials (RCT’s). Such trials are
considered to be the best available design for considering the effects of interventions
because, if they are properly carried out they best reduce the risk of bias (CRD
2009). This is so because, as Torgerson notes, the RCT provides a simple and
elegant design which ensures that, so long as the groups assembled through
randomisation are of an adequate size, then there can be confidence that any
differences observed between the groups will be a consequence of the intervention,
rather than as a result of any other variable, whether known or unknown. (Torgerson
and Torgerson 2008). The challenge of constructing meaningful HPTs using RCT
design was discussed earlier but in order to find the best and least biased available
evidence the review was limited to trials of this design.
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Exclusion criteria
-Studies in which there was not a comparator group 
-Studies in which the effects of a homeopathic substance were not compared to
either placebo or a different homeopathic substance.
- Studies in which participants were not described as randomly allocated to an
intervention.
- Studies in which participants were not blinded to treatment allocation
-  Studies published in languages other than English for which a full translation was
not available.
2.3 Search Strategy
Advice on a search strategy was sought from supervisors, who have expertise in
conducting published systematic reviews. Librarians at the University of York and the
University of Lincoln were also consulted for advice.
The document published by the centre for reviews and dissemination – CRD
guidance for undertaking reviews in health care (2009), was also used, to ensure
that current best practice in developing and operating search strategies was
followed.
The authors of the published systematic review of the quality of HPT’s (Dantas et al
2006) were contacted. These authors considered all papers published between 1945
and 1995. After personal contact they provided details of all of the papers considered
for their review. Attempts to contact them again for full details of their search strategy
proved unsuccessful. The review by Dantas et al had the advantage of being a multi
centre, multi language review, involving twelve reviewers. Although they do not
describe the full search strategy in detail, they describe manually searching books,
journals and conference proceedings, and using the relevant bibliographic databases
(general databases such as MEDLINE and specialist ones such as HomInform). 
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Given that this review was conducted by a group of international experts in
homeopathy, it is likely to be comprehensive and it is very unlikely that, with my
limited resources I would find anything new were I to repeat their search. 
I therefore decided to use the list of papers supplied by these authors as a starting
point and to develop a search strategy only for more recent publications.
Search terms.  The advice of specialist searchers and specialist subject librarians is
that the following search terms will pick up all papers relevant to homeopathy in
general.
1. homeopathy
2. Homoeopathy
And the following, using relevant truncation symbols 
3. Homeop
4. Homoeop
5. Homoop
6. Omeop
Within the homeopathic literature there is a debate about whether the word, which
arises from Greek terms homoios and pathos, should have the additional o before
the e, but both variants are used widely within the literature. To assist retrieval of non
English language papers the variants homoop and omeop were added.
In relation to Provings or homeopathic Pathogenetic Trials, the following search
terms cover the possible variants of terminology which are used in relation to this
subject
1. Proving ( with truncation symbol)
2. prufung
3. pathogenetic trials
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    B   Databases. A range of relevant databases contain information which is relevant
to homeopathy. 
Different databases have different systems for indexing papers and use a variety of
thesaurus and indexing systems to find papers using keywords. Each requires a
particular search strategy. The full strategy used to search for the relevant search
terms in each of the relevant databases, is contained in Appendices 1 -6.
 MEDLINE, produced by the United States National Library of Medicine, is
considered to be the primary source of global information from the
international literature, on medicine, healthcare and allied disciplines including
complementary therapies such as homeopathy (National Library of Medicine
2008). 
 AMED is a specialist database with comprehensive coverage of
Complementary medicine. 
 EMBASE covers a wider range of journals than MEDLINE, the overlap with
MEDLINE is only some 40%. EMBASE also has the merit of being a
specifically European database, an important consideration given that much
homeopathic literature originates in Britain, Germany, France and Italy.
 CINAHL is   the only one database which has a specific index term relating to
HPTs – the MESH heading homeopathic Provings is used. 
 Hominform is a specialist homeopathic database constructed in 1988 by the
Academic Departments of Homoeopathic Medicine of Glasgow Homoeopathic
Hospital. 
 LILACS (Latin American and Caribbean Health Sciences Literature). This
database includes papers published in Spanish and Portugese. All titles,
descriptors used for indexing, and some abstracts, are also translated into
English.  It is known that limiting searches to English language papers can
introduce language bias. (Egger et al 1997). Whilst the large databases such
as MEDLINE have some non English language journals, the numbers are
small. Moher et al (2003) consider the inclusion of papers in languages other
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than English to be especially important in systematic reviews of CAM’s.
Certainly homeopathy is used more widely in some parts of the world, than in
Europe and North America.  This includes Latin America and ideally it would
be important to include LILACS in any search strategy relating to this subject.
Searching for trials in LILACS has been demonstrated to improve systematic
reviews by finding  papers which meet inclusion criteria, but are not found
using other database searches in significant numbers of published reviews
(Manriquez 2008). 
Given these factors it is very likely that a full search including LILACS would
reduce bias and would result in the retrieval of additional studies meeting the
inclusion criteria. However, the practicalities of an unfunded project meant that
a full LILACS search was not feasible. Instead a search of LILACS using
English language terms only was undertaken.
The following databases were therefore searched, where possible for the period from
1996 to date.
Table 2.1 Databases used in the search, with date ranges
Database Date Range
OVID MEDLINE January 1996- May 2009 ( week 4)
AMED January 1996- May 2009 ( week 4)
EMBASE January 1996- May 2009 ( week 4)
CINAHL January 1996- May 2009 ( week 4)
HOMINFORM All dates 
LILACS January 1996- May 2009 ( week 4)
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2.4 Stages of the Search
The search was carried out in three stages
Stage one: The full search was carried out as described above. The results of all but
one of the database searches were imported into a Refworks database. The full set
of references from the aggregated searches was then de-duplicated. It was not
possible to import results from The Hom Inform database into Refworks other than
via the transfer of each individual data entry; nor was it possible to limit the
HomInform search to the relevant date range The HomInform results were therefore
screened separately.  
The results of hand searches and personal contact with authors were added to the
full list.
Stage Two. Screening. Where possible abstracts were screened to determine
whether papers met the inclusion criteria. Where a clear judgement could me made
papers that did not meet the criteria were rejected. Any papers which met the criteria,
or over which there was uncertainty, or for which abstracts were unavailable were
obtained in full. 
Stage Three. The full papers were then screened, and judgements made about
which papers met the inclusion criteria.  A second author was asked to verify the
screening process. This did not take place before the submission deadline but will be
completed shortly after, to assist a process of submission for publication in a journal.
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Table 2.2 Algorithm for screening of studies for eligibility
Assessment Comment 
Randomisation Yes      Unclear          No
                            
                               EXCLUD
E
Age – 18+
Yes      Unclear          No
                            
                               EXCLUD
E
Interventions
Name and strength
( potency) of homeopathic
medicine (exclude mother
tinctures)
Placebo described
Frequency and numbers of
doses described
Yes      Unclear          No
                            
                               EXCLUD
E
Outcomes: Clear quantitative
outcomes for both
intervention and comparator
groups
Yes      Unclear          No
                            
                               EXCLUD
E
Language: Full text of report
of trial available in English
Yes      Unclear          No
                            
                               EXCLUD
E
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2.5 Data Extraction
All data was extracted by the primary author ( JR). The methods used for each trial
were noted, including the method of randomisation. Methods of recruitment and
details of participants were noted, including details of any methods used to
determine the state of health of participants at the point of recruitment. The nature of
the intervention was described, including full details of the name and potency of the
homeopathic medicine, along with the source and details of the method of
preparation of the medicine. Details regarding the nature and preparation of placebo
were also described. Full details of primary and secondary outcome measures were
described.
 CRD note that the extraction of data is linked to assessment of study quality in that
both processes are often undertaken at the same time. (CRD 2009).An example of
the form that was developed for this review is provided in table 2.1 and it will be seen
that data and quality were assessed at the same time on a two part form with
separate areas for each.
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*For full details of the criteria used to make these judgements see appendix 2.1
36
Primary trial author and year of publication
Methods               
Participants
___________________________________________________________________________
Interventions
__________________________________________________________________________
Outcomes. 
___________________________________________________________________________
Notes
___________________________________________________________________________
Risk of bias
___________________________________________________________________________
Item                                      Authors Judgement                          Description
Adequate sequence                 YES/NO/UNCLEAR *       
___________________________________________________________________________
Allocation concealment          YES/NO/UNCLEAR*
___________________________________________________________________________
Blinding                                  YES/ NO/UNCLEAR*
___________________________________________________________________________
Incomplete outcome data      YES/NO/UNCLEAR*
___________________________________________________________________________
Screening of volunteers
for sensitivity                           YES/NO/UNCLEAR*
Table 2.1 Example Data extraction and risk of bias form.
2.6 Strategy for assessing study validity. 
The terms methodological quality and study validity are often used interchangeably.
Quality may refer to both internal and external validity.  Internal validity refers to the
degree to which results are likely to approximate to the truth (CRD 2009). For this,
the design and conduct of the study as well as the analyses of results must be as
free from bias as possible. External validity - the degree, to which the results of a
study can be applied in other settings, relates to the relevance of the populations,
interventions and outcome measures
 One of the most significant ways in which findings can be more reliably assumed to
be closer to the truth is through the reduction of bias. With studies involving human
subjects there are a range of types of bias which can skew the results of research,
often significantly. 
The sources of such bias can be summarised as arising from  subjects, researchers
and measurements (Peat et al 2002) and the types of bias have also been
categorised in the following way (Khan et al 2003)
1. Selection (or allocation) bias. This refers to systematic differences between
comparison groups in some measure which may affect the outcome being
measured.
2.  Performance bias. This refers to differences in the care or interactions
between clinicians and/or researchers and the different comparator groups.
3.  Measurement bias (also known as detection bias). This refers to differences
in the measurement of outcomes between the comparator groups
4. Attrition bias. (also known as exclusion bias). The bias can arise if features of
the intervention (such as side effects) lead to a higher drop out/ withdrawal
rate from one of the comparator groups.
Individual studies are subject to all of these types of bias. It is important, in trying to
make realistic assessments of the efficacy and effectiveness of health care
interventions to make some kind of assessment of quality in relation to these aspects
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since several studies have indicated that health care trials of poor methodological
quality offer exaggerated estimates of treatment effects (Schultz et al 1995)
One of the key aims of systematic reviews is also to reduce bias.(Khan et al 2003)
and, as well as quality tools for the reporting of individual trials there are a range of
tools available to assessors to assist in the assessment of trials by reviewers.
There are a number of reasons for assessing the level of bias and the quality within
the primary studies which are conducted in any review. The inclusion of the results of
a series of poor quality and biased studies in any meta- analysis or quantitative
analysis which follows a review may of course simply amplify the bias.  Other
reasons suggested for assessing quality of primary studies include:
- Determining a minimum threshold of quality in terms of study design which will
form the basis of selection for a review
- To explore quality differences as an explanatory framework in relation to the
heterogeneity of study results
- Weighting study results according to quality in meta- analyses
(Khan et al 2003)
Many methodological quality instruments and scales have been developed to assess
these parameters in trials. A widely used scale is the one developed by Jadad and
colleagues at the University of Oxford. This offers a simple scoring system with five
possible points awarded for elements which appear in the published version of the
trial. Points are scored if a study is described as randomised, described as double
blind and if it offers a description of withdrawals and dropouts. Its simplicity and
relevance for the task has led to it becoming the most widely used instrument, and
as of 2008 the original paper had been cited over 3000 times (Olive et al 2008). 
It is often used not only as an assessment of some of the key elements of validity but
to provide a cut off point for using trials in reviews and meta- analysis. Systematic
reviewers will often use a score of 3 as a minimum for including trials in reviews.
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(Berger 2006). The JADAD scale has the merits of simplicity, credibility and a clear
focus on those aspects of trial design which are most likely to reduce bias. The
elements identified in the JADAD scale are important but there are criticisms of
scales and scoring systems in relation to validity. The guidance from the Centre for
Reviews and Disseminations suggests that “The use of scales with summary scores
to distinguish high and low quality studies is questionable and not recommended”
(CRD 2009). They suggest instead that individual aspects of methodological quality
should be considered when assessing quality and at the stage of data synthesis. The
impact of quality on findings can then be assessed by sub group analysis.
Whilst it is important to consider all of the aspects of quality which consensus
methods have agreed to be important for clinical trials, it is also important to be
sensitive to the specific elements of quality which might be unique to the types of
studies under consideration. It was noted in the background chapter that HPT’s pose
a unique set of challenges and questions. Researchers have noted that there has
been a lack of consensus and a wide variety of methodologies employed in the
design and conduct of HPT’s (Wieland 1998)
Expert groups, and those who have conducted numbers of HPTs have made several
sets of recommendations designed to improve the quality of HPT’s. (Wieland 1997,
ECH 1995, Riley 1997) In their systematic review of the quality of HPT’s  Dantas et
al, building on earlier work, developed a methodological quality index which included
the usual features of randomisation and blinding but also included a score relating to
the “ criteria for the selection of effects “.(Datas et al 2007)
As noted in the background chapter the issue of susceptibility is crucial in the design
of HPT’s and methods for dealing with this issue should be reported in HPTs.
According to homeopathic theory this would seem to be the factor which would have
the greatest impact on outcomes.
Therefore, in this review, the quality of each included study was assessed in relation
to randomisation and allocation concealment, blinding, strategies for dealing with
missing outcome data, and strategies for determining the sensitivity of participants to
the medicine used in the trial. A risk of bias form was completed for each study to
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record details and a judgment of yes, no, or unclear was made in relation to the
achievement of each of these elements. (Table 2.1) 
Full details of the criteria which were used to make these judgements are contained
in appendix 7
2.7 Strategy for data synthesis
Synthesis involves the drawing together of disparate elements, and the summarising
of the findings of all of the studies included in the review. In evidential terms it is
viewed as preferential if some kind of quantitative synthesis can be arrived at using
statistical techniques such as meta- analysis. This is only possible where the
individual studies do not have methodologies and /or results which are too disparate
or heterogeneous. If the studies are too diverse to allow for meta-analysis then a
narrative summary only should be provided.
For this review a narrative synthesis was developed initially. Tables and graphs
comparing studies in relation to: patients, interventions, comparators, and outcomes
were constructed and follow in the results section. A discussion and analysis of the
design and findings of the included studies follows.
2.8 Heterogeneity.
It is important to consider heterogeneity when comparing studies. Heterogeneity
refers to the amount of difference or diversity between different studies in terms of
reported outcomes. It can arise for various reasons - it may be related to differences
in study populations, in the methodology of the studies and in the outcome measures
used, as well as to chance variation. (Higgins et al 2003). The clinical heterogeneity
which may arise for these reasons can be assessed and quantified statistically. The
I2 statistic, for example, calculates the amount of variability in the estimates of effect
that can be attributed to heterogeneity other than chance. Guidance has been
published which suggests that values up to 40% may be unimportant, up to 60%
deemed as moderate and over 75% considerable. (Higgins and Green 2008)
40
One of the advantages of graphical displays such as forest plots is that they offer
clear visual evidence of the level of heterogeneity – where there is little overlap
between confidence intervals this is a sign of high heterogeneity. Forest plots were
constructed for this review as part of a meta-analysis.
2.9 Meta analysis
The amount of heterogeneity also determines the methods used to treat data in any
meta-analysis. If heterogeneity does not exist or is limited a statistical meta-analysis
can be performed using a fixed effects models (which assume that all studies under
analysis are estimates of a single or very similar population).  Where there is clear
heterogeneity, meta- analysis can still be performed but using  random-effects
models to account for the greater uncertainty in the individual estimates In this
review it was possible to pool some data for two of the key outcome measures:
overall proving reactions and symptoms typical of the test medicine. Forest plots
were constructed, using both fixed and random effects.
Where data is pooled from trials measuring the same outcomes on the same scale
straightforward mean differences can be calculated; these are often weighted
according to trial size or levels of statistical variance between trials, to arrive at
weighted mean differences (WMDs). In this review effect sizes in the form of the
alternative standardised mean differences (SMDs), and 95% confidence intervals,
have been calculated where possible. SMDs allow for comparisons across different
outcomes measures relating to the same variables of interest, (CRD 2009) and this
is appropriate because the trials assessed for this review used a variety of different
measures. 
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CHAPTER THREE RESULTS
Database Date Searched Number of papers 
retrieved
Full Details
OVID Medline 31/5/09 44 Appendix 1
AMED 1/6/09 323 Appendix 2
Cochrane register of
controlled trials
14/6/09 143 Appendix 3
EMBASE 17/6/09 38 Appendix 4
CINAHL 17/609 56 Appendix 5
Hominform 12/6/09 503 Appendix 6
After de-duplication a total of 503 papers were left for screening.Screening of the
abstracts and/or full texts of these papers against the inclusion criteria for this review
led to the exclusion of 487 of them. 17 papers were retrieved and read in full. One of
these was excluded (Koster et al 1998) because it was a report mid way through a
trial, with no results. Efforts to contact the author and searches for any published
version of the final outcomes were unsuccessful. Six other papers were excluded
because they did not use appropriate design with random allocation of participants to
intervention or placebo groups. Personal contact with the author of two of the papers
which had met the inclusion criteria, led to the inclusion of a further paper recently
published in German – the author provided a full translation. Four of the papers took
the approach of combining reports from two separate trials into a single paper,
meaning that the 11 papers included in the review covered a total of 15 trials. All of
the papers were published in journals.
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Title and abstracts identified and
screened  n  =503
Publications meeting inclusion
criteria n =11
Full copies retrieved and
assessed for eligibility n =  17
Excluded n=  7
Not relevant design n=6
No outcome/intervention or
treatment n= 1
Excluded n = 487
Additional studies
identified
Contact with experts n = 1
From searching in
reference list of retrieved
studies n=0
Trials included in the systematic
review by Dantas et al n =156
Excluded from this review n= 156
Extra Trials included in this
review from the Dantas review
n = 0
Figure 3.1 Flowchart of included studies.
Summary of included studies.
3.1 Authors There were 8 different primary authors, with multiple studies by Vickers
(primary author on two studies) and Walach (primary author of 3 studies and
contributing author on 2 others)
3.2 Settings
The studies took place in a variety of countries: 7 in the UK, 3 in Germany, 3 in Italy
and 1 in both the UK and Israel. 
3.3 Participants
It is clear from table 3.2 (below) that studies involved more females that males. From
the available data, 395 participants were female and 182 male, proportions of 68.5%
and 31.5%. Walach (2004) did not report on gender and Walach (2001) reported
proportions of 49% and 66% female in two different samples, but did not give actual
numbers. From the remaining 13 studies, the percentage of females in the sample
was over 75% in four of the studies. (Vickers Van Haselen 2001, Brien 2003, Walach
2008, Mollinger 2009).  9 of the 13 studies which reported had more female
participants that male. Just one of the studies (Vickers, Mccarney 2001) had over
60% males.
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Publications included in the
reviews
n =11
Number of studies included in the
review n = 15
Table 3.2 Gender of participants in included studies
Author Female Male
Wallach 2001HPT1 2 samples n unclear
Sample A homeopathic
community =49%
Sample B naive subjects
=66%
Sample A =51%
Sample B = 34%
 Vickers Van Haselen 200 HPT2 80 (78%) 24 (22%)
Dominici et al 2006 HPT 3A
                                                  HPT3B
9 (64%)
8 (62%)
5 (36%)
5 (38%)
Fisher 2001  HPT4A
                                  HPT4B
14 (70%)
11 (55%)
6 (30%)
9 (45%)
Brien 2003  HPT5 164 (79%) 42 (21%)
Goodyear  1998  HPT6 23 (48%) 24 (52%)
Walach  2004  HPT7 Not reported Not reported
Signorini 2005 HPT 8A
                        HPT8B
9 (50%)
11(44%)
9 (50%)
14 (56%)
45
Walach 2008 HPT9A
                                  HPT9B
17 (100%)
20 (55%)
0 (0%)
16 (45%)
Vickers McCarney 2001 HPT10 19 (38%) 31 (62%)
Mollinger 2009  HPT11 19 (76%) 6 (24%)
Total 395 (68%) 182 (32%)
Despite it being standard practice to include only healthy adults in pathogenetic trials
only one study author reported attempts to define and operationalise healthy
participants.  Fisher (2001) included only those who scored within one standard
deviation of the mean value for UK adults on at least seven of eight subscales of the
SF36 short form medical outcomes questionnaire. In addition participants in this trial
had to undergo screening for full blood count, plasma urea and electrolytes and
return these within the normal range. Brien (2003) used an unspecified questionnaire
to screen for stable good health. Walach (2001) used a recently validated personality
questionnaire – the Freiburg Personality Inventory (FPI) as part of the trial, but not as
part of the inclusion/exclusion process.
All of the trials used inclusion and exclusion criteria in order to try to recruit only
adults in stable good health. (see table 3.1 below). It will be seen that whilst each
trial used a unique set of criteria there were some commonalities. 5 of the studies
excluded participants who were pregnant or nursing and one of these (Walach 2001)
extended this to include planned pregnancies as well as current ones. The use of
different kinds of medicines was approached in a range of ways. 2 of the trials
(Walach 2001 and Fisher 2001) excluded those using recreational drugs though
Fisher made an exception for tobacco in regular smokers, and moderate use of
alcohol. 9 of the studies adopted explicit exclusion criteria relating to the use of
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prescribed medication, though there were variations in the way in which these were
worded and again some exceptions were made. Walach (2001), Mollinger (2009)
and Dominici (2006) mentioned any use of medication; Vickers and Van Haselen
(2001) mentioned regular use; Fisher (2001), Brien (2003) and Goodyear (1998)
referred to the use of medication in the previous 4 weeks; for Signorini (2006) it was
2 months, and for Vickers and McCarney it was only concurrent use during the trial
that was excluded. In relation to the specific use of Homeopathic medicines other
than the trial medicine this was mentioned in 11 of the 15 trials but there were again
differences in the period exclusion. Vickers and VanHaselen (2001) and Walach
(2008) simply referred to regular use. Dominici (2006) excluded anyone using
homeopathic medicines in the last 6 months, whilst for Brien (2003) and Goodyear
(1998) it was just 4 weeks. For Walach (2004) it was 10 weeks. 
Table 3.3  Comparison of exclusion criteria used in individual trials in relation to
health status of participants.
Trial    Exclusion Criteria
Walach
2001 HPT1
 Use of recreational drugs or any conventional medication  
 Abuse of alcohol, or pharmaceutical drugs               
 Pregnancy, (present or planned), or nursing    
 Stress,  Irregular life
Vickers
2001 HPT2
 Self report of any perceptible illness
 Regular use of any form of homeopathic, herbal or medical drugs ( stable
use of contraceptive pill for at least one year allowed)
 Formal training in or explicit knowledge of homeopathy
 Anticipated major life change during the trial 
 Pregnancy or nursing
 Participation in other HPTs or clinical trials in previous 3 months
 Lack of mental capacity to understand the nature or consequences of the
trial
Dominici
2006 HPT 3A
 Use of contraceptive pill or any drugs
 Elective medical treatment during the trial period
 No homeopathic remedy within the previous 6 months.
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 Any mental pathology or chronic physical pathology in the judgement of the
participant or the trial supervisor.
Dominici
2006 HPT3B
 As for HPT3A ( above)
Fisher 2001
HPT4A
 Current medical treatment
 Prescription only medication in previous month
 Use of recreational drugs (except alcohol in moderation and tobacco if
established smoker.
 Surgery in preceding 6 weeks
 Pregnancy, breast feeding.
 Values more than one standard deviation  outside the mean value on the
SF36
Fisher 2001
HPT4B
 As for  HPT4A ( above)
Brien 2003
HPT5
 Any medication use ( conventional, herbal or homeopathic) in the previous
4 weeks ( contraceptive pill allowed)
 Illness during trial requiring excluded medication
 Current pregnancy/nursing.
Goodyear
1998 HPT6
 Any medication use ( conventional, herbal or homeopathic) in the previous
4 weeks 
 Self report of any perceptible illness
Walach
2004 HPT7
 Use of any homeopathic medicine or participation in HPT in previous 10
weeks.
 Any organic pathology
Signorini
2005 HPT8A
 Chronic disease in the previous year.
 Hospital treatment( past 6 months), vaccination ( past 3 months), dentistry
( past month)
 Medication in last 2 months ( 6 months if homeopathic meds in potencies
above 200C
Signorini
2005 HPT8B
 As in HPT8A ( above)
Walach  Use of homeopathic medicine in previous 4 – 12 weeks ( depending on
potency)
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2008 HPT9A  Regular use of conventional, recreational or homeopathic medicines.
 Any acute or chronic medical condition
Walach
2008 HPT9B
As for HPT9A ( above)
Vickers
2001 HPT10
 Self report of any perceptible illness
 Concurrent use of any form of homeopathic, herbal or medical drugs
( stable use of medication and stable illness was allowed following an
assessment by the study doctor)
 Anticipated major life change during the trial 
Mollinger
2009 HPT11
 acute illness,  or chronic disease  necessitating regular medication
 intake of conventional medication except contraceptives,
 pregnancy or nursing, 
 extraordinary strain from family or job demands, 
 intake of any homeopathic remedies at time of trial, 
 intake of homeopathic remedies at C30 up to 4 weeks previously, intake of
homeopathic remedies at C200 up to 2 months previously, intake of
homeopathic remedies at C1,000 or higher up to 3 months previously
Other authors made distinctions, dependent on the strength of the homeopathic
medicine. So Signorini excluded us of any homeopathic medicine in the previous 2
months, but this was extended to 6 months if the strength of the homeopathic
medicine was 200c or higher. In a similar way Walach (2008) and Mollinger (2009)
had varying exclusion periods, ranging from 4 weeks up to 12 weeks for the higher
strength homeopathic medicines.  As a corollary to the exclusion of those using
homeopathic medicines for treatment, 2 authors excluded those who had
participated in other HPT’s in the past 3 months or 10 weeks ( Vickers and Van
Haselen 2001, Walach 2004 respectively)
Vaccination and dentistry were explicitly excluded by just one author (Signorini
2006). Vickers and Van Haselen (2001) were the only authors to explicitly refer to
mental capacity 
3.4 Susceptibility to a homeopathic medicine.
None of the included studies report any methods for screening participants for
sensitivity or susceptibility to the specific medicine used in the trial.
3.5 Interventions and comparators
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Of the 15 studies, 13 studies compared single homeopathic medicines with identical
placebo medicines (an identical sugar pill or liquid solution). 2 studies (Walach 2008
and Mollinger 2009) involved three arm trials which compared 2 separate
homeopathic medicines with placebo. Table 3.4 lists the schedules for individual
studies.
9 of the studies used a fixed dosage schedule with participants taking medicines
twice daily (Walach 2001; Brien 2003; Goodyear 1998) or 3 times daily (Vickers, Van
Haselen 2001; Fisher 2001, Vickers, McCarney 2001) for the duration of the trial. 5
of the papers, covering 6 separate trials report flexible schedules with participants
instructed to stop use of medication if symptoms occurred.
10 of the trials involved the use of homeopathic medicine in a 30C potency, and 4
used medicines in a 12C potency. No other potencies were used. Belladonna was
chosen as the test medication in 3 trials (Brien 2003, Goodyear 1998 and Walach
2001). The remaining trials all used different, single medicines.
Table 3.4 Interventions. Medicines and dosages.
Walach 2001   HPT1                      Belladonna 30C                           Twice daily          
Vickers 2001 HPT2                        Mercurius   12C                           Three times daily
Dominici 2006  HPT 3A                 Etna Lava 30C                             Three times daily but stop if new
                                                                                                symptoms appear
Dominici 2006 HPT3B                  Hydrogenium Peroxidatum 30C    Three times daily but stop if new
                                                                                                symptoms appear
_____________________________________________________________________________________
Fisher 2001 HPT4A                        Acidum Malicum 12C                   Three times daily
Fisher  2001 HPT4B                      Acidum Ascorbicum 12C              Three times daily
Brien 2003  HPT5                           Belladonna 30C                            Twice daily
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Goodyear  1998 HPT6               Belladonna 30C                            Twice daily
Walach 2004 HPT7                       Cantharis 30C                               Twice daily
Signorini 2005 HPT8A                  Piper Methysitcum 30C/               Four times daily, increased to six after
Signorini 2005 HPT8B           Plumbum Metallicum 30C                    third day but stop if strong symptoms
Walach 2008 HPT9A              Ozone 30C                                  Several times daily at discretion of 
                                                                                                Participant, for no more than 3 days
Walach 2008 HPT9B                     Ozone 30C                                   
Vickers 2001 HPT10                      Bryonia 12C                                 Three times daily
         
Mollinger 2009 HPT11                  Natrum Muriaticum 30C/              Single dose day 1. Twice daily day 2
                                           Arsenicum Album 30C                 onwards or until symptoms appear.
Table 3.5 Outcome measures used in included trials
Trial Outcome
measure
Timing Dimensions measured for primary
and secondary outcomes
Walach 2001 HPT1 Unstructured
diary
Daily Number, frequency and intensity of sx
Vickers 2001 HPT2 Questionnaire
with 5 sx
deemed true
and 5 deemed
false for the
medicine
Daily Frequency of each sx
Intensity on 3 point scale
Dominici2006 HPT 3A Structured
diary
Daily Existing symptoms increasing in
intensity/duration
Previous sx that had not occurred for
at least 1 yr.
Current sx that disappeared during
HPT
New sx unfamiliar to participant
Exceptional sx
Dominici 2006 HPT3B Structured
diary
Daily As HPT3A above
Fisher 2001HPT4A Structured and
unstructured
Daily Severity, frequency, duration, modality
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dairies and causal relationship to treatment.
Fisher 2001HPT4B Structured and
unstructured
dairies
Daily Severity, frequency, duration, modality
and causal relationship to treatment.
Brien 2003 HPT5  Questionnaire
with 5 sx
deemed true
and 5 deemed
false for the
medicine
Daily Proving reactions: defined as 2 true
sx on at least 2 consecutive days with
no more than one false sx in 21 day
study period.
Goodyear 1998
HPT6
Questionnaire
with 5 sx
deemed true
and 5 deemed
false for the
medicine
Daily Proving reactions: defined as 2 true
sx on at least 2 consecutive days with
no more than one false sx in 14 day
study period.
Walach 2004 HPT7 Unstructured
diary
Daily Symptoms deemed typical of the
medicine.
Signorini 2005
HPT8A
Unstructured
diary
Daily Selected notes containing sentences
describing symptoms which were very
unusual or never happened before.
Signorini 2005
HPT8B
Unstructured
diary
Daily As HPT8A above
Walach 2008 HPT9A Unstructured
diary and
interview by
supervisor
Daily Particular attention paid to symptoms
never experienced before.
Walach 2008 HPT9B Unstructured
diary and
interview by
supervisor
Daily Particular attention paid to symptoms
never experienced before.
Vickers 2001 HPT10 Questionnaire Any point
during or
after 2 x 1
Participant guess as to which of two
medicines taken was homeopathic
medicine and which placebo.
52
week trial
periods
Confidence in judgement on 3 point
scale
Mollinger 2009
HPT11
Unstructured
diary and
interview by
supervisor
Daily Judgement by homeopathy expert as
to whether symptoms were typical or
not for the homeopathic medicine
taken.
Outcomes 
As illustrated by Table 3.5, a range of instruments were used to capture the
experience of symptoms by participants during the pathogenetic trials. 12 of the 15
trials involved the completion by participants of structured and/or unstructured diaries
on a daily basis, allowing for the recording of any symptoms which occurred.  4
papers reported  trials in which certain symptoms were pre-specified as  typical of
the medicine being tested; participants were then asked  to record whether a range
of symptoms typical and untypical for the medicine were experienced. Outcomes in
these trials involved comparing numbers of typical and untypical symptoms across
the verum and placebo groups (Goodyear 1998, Vickers, Van Haselen 2001, Brien
2003, Walach 2008). Fisher (2001) developed a pathogenetic index which was
adapted from an index for judging the causality of adverse drug reactions. (Naranjo
1981). The index offered a score based on judgements of both participants and
supervisors. Only 1   trial (Signorini 2006) was designed with outcome measures to
capture symptoms by the general categories used in homeopathic literature (e.g.
new, old, unusual, cured, intense,)
3.7 Design
All of the trials included in this review were randomised trials. Authors reported using
randomisation to allocate participants to homeopathic medicine or identical placebo
medicine. Authors are divided with regard to the use of parallel or crossover designs
for these types of trials. Walach (2001), Fisher (2001) and Vickers, McCarney (2001)
report crossover designs. The remaining trials were all designed as parallel group
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trials. Table 3.2 shows the range of baseline, intervention and follow up periods, of
the trials.
                                                      
Table 3.6 Timescales of included trials.
Trial Run in period Intervention period Follow up period
Walach 2001HPT1 2 wks observation 2 x 1 wk ( crossover)
with 1 wk run in and
1 wk washout
-
Vickers, Van Haselen
2001 HPT2
1 wk placebo I wk with 1 wk
placebo run out
-
Dominici 2006 HPT3 2 wks observation 2 days or until
symptoms appeared
2 months
Fisher 2001 
HPT4A AND HPT4B
Unspecified period –
observation only
4 x 1 wk (crossover) 1 wk – extended to 3
if symptoms
continuing 
( report of any further
symptoms after next
60 days )
Brien 2003 HPT5 1 wk placebo 2 wks 1 wk
Goodyear 1998 HPT6 None 2 wks -
Walach  2004 HPT7A AND
HPT7B
1 wk observation 2wks -
Signorini 2005 HPT8A AND 1 wk observation 1wk 1wk
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HPT8B
Walach 2008 HPT9A AND
HPT9B
1 wk observation 3 days or until
symptoms appeared
2 wks
Vickers,McCarney
2001HPT10
None 2 x 1 wk ( crossover)
Mollinger 2009 HPT11 None 2 days 2 days
3 of the 15 trials had no run in period, and did not measure any outcomes during a
baseline period. Most of the trials, (10 from 15) had a run in period. 1 week was the
most common length: 3 authors used a 1 week observation period in 5 separate
trials; and 2 authors used a 1 week run in period with the use of placebo. 2 authors
used a longer 2 week run in period for observation. One of the trials discussed an
observation period between recruitment and the start of the trial but did not specify
the length of this.
Turning to the length of intervention periods in the included trials, the majority (11 of
the 15) used 1 or 2 weeks. 4 trials used a 2 week intervention period, a single trial
used a 1 week period, with a further trial using a one week active intervention period
followed by a 1 week placebo run out. The 5 crossover trials all used one week
intervention periods interspersed with 1 week washout periods.
3.8 Risk of bias in included studies
Methodological quality was assessed using the key criteria suggested by the
Cochrane Collaboration Tool for Assessing Risk of Bias (Higgins JPT, Green S,
2008) and as outlined in the methods section. Full details for each study are in the
risk of bias tables which form part of the table of included studies. Appendix 7
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3.9 Sequence generation and allocation concealment
In 14 of the 15 included trials details of the sequence generation and the
concealment of randomisation were reported and explained in sufficient detail to
merit a positive judgement in relation to these features. Just one of the trials
(Vickers, McCarney 2001) did not provide sufficient detail regarding the method of
randomisation to be able to make a clear judgement about the method of sequence
generation in relation to allocation to groups.
3.10 Blinding and predicting assignment.
All of the trials involved procedures for double blinding and report techniques for
blinding trial supervisors and participants. The issue of verification of blinding was
touched on previously. The ability of participants to guess which intervention they
have received is sometimes used as a measure of blinding. This makes sense in
certain circumstances, particularly at the beginning of trials. However, if participants
receive interventions which do have significant effects ( beneficial or adverse) which
provide signals to them that they are receiving some kind of active intervention then
logically they are more likely to guess their assignment, if the comparison is between
placebo and verum. It is known that when side effects are prominent patients can be
unblinded in clinical trials (Hertzman and Feltner 1997). Walach (2008) notes that
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HPTs are designed to actually elicit what would be deemed as side effects in a
clinical context, and that using participants judgements about assumed group
assignment cannot then sensibly used to verify blinding.
The alternative method of asking people who were not trial participants to guess the
difference between placebo and verum preparations was used by Vickers and Van
Haselen (2001) and Brien 2003 who used an independent group from the MRC
clinical trials unit to verify indistinguishability of placebo and verum preparations.
Fisher (2001) reports two trials in which correct guessing of treatment allocation
(placebo vs. verum) by volunteers was 48% and 50% respectively. It is not fully clear
at which point in the trial this guessing was carried out.
 Vickers and McCarney (2001) actually used participant’s guesses about group
assignment as the primary outcome measure to determine whether Homeopaths can
detect homeopathic medicines. In their study 70 homeopaths were randomised of
whom 50 completed the trial. 60% correctly identified the bottle containing the
homeopathic remedy Bryonia 12C.
3.11 Follow up and exclusions
The issue of withdrawal and loss to follow up from trials of health interventions is
important. If data is excluded from analysis because of loss to follow up, there may
be systematic differences between such data across the comparator groups. If
differences in interventions and outcomes exist they may lead to attrition bias. A
clear example is one in which high numbers of people withdraw from an intervention
group due to adverse events. If results are analysed only on the basis of those who
complete the trial, such an analysis is likely to favour the intervention group in many
trials. A trial of good quality should have clear processes in place for gathering full
data as far as possible, and thus minimising attrition bias and its effects (Wright and
Sim 2003).  Intention to Treat (ITT) analysis is recommended so that data on trial
participants is analysed according to the group to which they were randomised.
Imputation of missing data can be made, based on explicit criteria. As a minimum
trial authors should report numbers and proportions lost to follow up across the
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different comparator groups so that reviewers can make judgements about whether
the number and pattern of participants lost to follow up us likely to have led to bias
In the trials considered for this review, a total of 692 participants were enrolled in
studies. Total loss to follow up was 118 and 574 participants completed the trials,
meaning that there was a total 17% loss to follow up. Table 3.7 lists the numbers of
and reasons for , loss to follow up in included studies.
It can be seen from this table that the most common reason for loss to follow up is
failure to complete the daily diary or questionnaire adequately. Adverse events were
explicitly noted as a reason for loss to follow up in 2 trials by Signorini (2006).
Adverse events are discussed in more detail in the next section.
Table 3.7 Loss to follow up in included studies.
Trial No of
participants
enrolled
Number lost to
follow up by group
(and % of total)
Reasons for 
Loss to follow
up
Walach
2001HPT1
118 31(26%)
Crossover trial.
Timing of
withdrawals not
specified
10= non return of diairies,21 diaries
contained incomplete data.
Vickers, Van
Haselen
2001HPT2
118 Verum n=8 (13%)
Placebo n=6
(10%)
Authors report that all occurred in
placebo run in week and were balanced
across two groups which were
comparable at baseline
Dominici
2006HPT3
16 0 (0%) N/A
Fisher
2001HPT4A
20 n=3 (14%)  Failure to attend interview twice (2)
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Crossover trial.
Timing of
withdrawals not
specified
Failure to complete diary(1)
Fisher
2001HPT4B
20 n=5 (25%)
Crossover trial.
Timing of
withdrawals not
specified
Request of participant (3)
Failure to complete diary(2)
Brien 2003HPT5 234 Verum n=25
(20%)
Placebo n=22
(17%) 
Too busy ( placebo =9, verum =10)
Lost medication ( p = 1 v =4)
Non compliance ( p =1 v =3)
Breeched exclusion criteria (p=1 v=2)
Unknown ( p = 10, v =6)
Goodyear
1998HPT6
60 Verum n=10(33%)
Placebo n=3(10%)
Authors unable to determine
Walach
2004HPT7
11 unclear N/A
Signorini
2005HPT8A
32 Verum n=3(19%)
Placebo n=5
(31%)
Verum -Adverse reaction (1) – pain and
swelling of knee.
Placebo:Tonsillitis(1) Use of anti-
inflammatory drugs (1) Absence of
baseline history (1) code breaking(1)
Signorini
2005HPT8B
31 Verum n=7 (53%)
Placebo n= 5
Verum – adverse event – neuralgia (1)
withdrawals, no reason given (6)
 Placebo ( same placebo group used for
trial HPT8A and HPT8B):Tonsillitis(1)
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(31%) Use of anti-inflammatory drugs (1)
Absence of baseline history (1) code
breaking(1)
Walach
2008HPT9
36 0 (0%) N/A
Walach
2008HPT9
17 0 (0%) N/A
Vickers,
McCarney
2001 HPT10
70 20 (29%)
Crossover trial.
Failure to return questionnaire.
Concomitant disease. Change in
eligibility. Withdrawal of consent.
Mollinger
2009HPT11
25 0(0%) N/A
3.12 Adverse events. See table below.
Table 3.8 Adverse events in included studies
Trial Number of adverse events Comments
Vickers, Van Haselen 2001
HPT2
N= 62 ( in 48 different
participants)
During placebo run in n=22
Verum n=22
Placebo n=19
No significant difference
between verum and placebo
groups.
Fisher 2001 HPT4a No serious adverse events 1 participant withdrawn due
to intercurrent illness. ( fever,
headache runny nose). On
breaking code found to be in
placebo group.
Fisher 2001 HPT4B No serious adverse events 1 participant withdrawn due
to intercurrent illness.
(itching, poor concentration,
muscular pain). On breaking
code found to be in placebo
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group
Brien 2003HPT5 37 ( in 253 participants) Two required hospitalisation
( 1 in verum and 1 in placebo
group)
No significant difference
between verum and placebo
groups
Signorini 2005 HPT8A 1 ( in 16 participants) in
verum group
0 (16 participants) in placebo
Pain and swelling of knee.
Vickers, McCarney 2001HPT10 3 ( in 70 participants) All in washout period (no
intervention) following verum 
Adverse events can be a significant reason for loss to follow up in trials. A total of
106 separate adverse events were reported by different participants in five trials
considered for this review. The remainder of the trials did not report on this item.
Vickers and Van Haselen (2001) reported that adverse events which led to the use of
other medication or to withdrawal from the study were recorded . Causal
relationships between such adverse events and the study medication were
assessed. They reported 62 adverse events in 48 subjects but no significant
differences between placebo and verum and no evidence of adverse events in those
taking homeopathic mercury. Fisher (2001) reported no serious adverse events.
Brien (2003) defined adverse events as those symptoms which required medication
other than the study medication and also true symptoms that led to withdrawal from
the study. They reported 37 AEs including two serious issues requiring
hospitalisation ( one in the verum and one in the placebo group). They reported no
significant difference in adverse events between verum and placebo or between
those displaying a proving reaction and those not. Signorini et al (2005) reported just
one adverse reaction, occurring in the verum group. Vickers, McCarney et al (2001)
reported adverse events in three participants who all continued with the trial, two to
completion. In each case the event occurred during a washout period following the
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period of taking verum. The other 7 papers included  this review do report the
occurrence or management of adverse events.
None of the German studies discussed the issue of adverse events and only 2 of the
larger UK studies noted any significant numbers of adverse events. The aim of
pathogenetic trials is to produce pathogenetic symptoms and it might be expected
that significant pathogenetic effects might be classed as adverse events. A clear
definition of an adverse event and  the difference between a pathogenetic symptom
and an adverse event is recommended in  ECH guidelines and this would help the
clarity of reporting.  
It is notable that the study which reported the highest number of adverse events
( Vickers and Van Haselen 2001) reported that the study nurse specifically asked
participants at the end of each week about the occurrence of adverse events.
The two studies which reported significant numbers of adverse events (Vickers and
Van Haselen 2001, Brien 2003) both took the approach of recording as an adverse
event that which led to the use of medication ( other than the study medication) or to
withdrawal from the trial. Neither of these studies reported a significant difference
between verum and placebo groups in the occurrence of adverse events. This could
be taken as evidence that adverse events were unlikely to have biased the outcomes
in significant ways. It could also be taken as a form of  evidence that homeopathic
medicines do not lead to significant  pathogenetic effects any more than placebo
interventions do.
3.13 Screening for sensitivity to the test medicine.
This item was noted above in relation to the discussion of inclusion and exclusion
criteria. It is deemed a critical item which will affect the ability of trial designs to
detect outcomes. It is therefore included also as one of the items used to judge the
quality of trials.None of the included studies report any methods for screening
participants for sensitivity or susceptibility to the specific medicine used in the trial.
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3.14 Summary of the overall quality of studied included in the review.
Overall, the studies which met the inclusion criteria for this review were of good
quality in relation to methods of randomisation, allocation concealment, and blinding.
( see table 3.9)  Methods of dealing with loss to follow up and adverse events were
more variable. Clear definitions and methods for checking for adverse events during
trials were missing in 8 of the papers included.  Five of the trials reported loss to
follow up of 20% or greater. 
Table 3.9 summary of judgements relating to quality of included studies
Trial Adequate
sequence
generation
Allocation
concealment
Blinding Procedures
for dealing
with
incomplete
outcome
data
Screening of
participants
for sensitivity
to
homeopathic
medicines
Walach 2001HPT1 YES YES YES NO NO
Vickers, Van
Haselen 2001 HPT2
YES YES YES YES NO
Dominici 2006 HPT3 YES YES YES NO NO
Fisher 2001 
HPT4A AND HPT4B
YES YES YES UNCLEAR NO
Brien 2003 HPT5 YES YES YES YES NO
Goodyear 1998 HPT6 YES YES YES UNCLEAR NO
Walach  2004 HPT7A
AND HPT7B
YES YES YES UNCLEAR N0
Signorini 2005 HPT8A
AND HPT8B
YES YES YES NO NO
Walach 2008 HPT9A
AND HPT9B
YES YES YES YES NO
Vickers,McCarney UNCLEAR YES YES YES NO
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2001HPT10
Mollinger 2009 HPT11 YES YES YES YES NO
3.15 Study results. Primary and secondary outcomes
The primary outcomes and other items of interest ,as discussed in the methods
section, are reported here. Authors  most commonly reported outcomes  using mean
values. 
Descriptive statistics and narrative analysis are provided followed by the pooling of
data and  statistical meta-analysis where possible. 
3.15.1 Overall measures of ‘proving’ reactions
One approach to the design of HPTs is to pre define a proving reaction and then to
use the number of participants who display this proving reaction as an  outcome
measure. 3 of the included studies  measured this ( see table 3.10)
Table 3.10 “proving” reactions in individual trials.
Study Number of participants
demonstrating a proving
reaction
Definition of proving reaction
Vickers Van Haselen 4/52 ( 8%)    verum vs.
 1/52 (2%)    placebo
2 true symptoms on at least 2
consecutive days. A
difference score of more than
10 between trial period and
baseline on this measure
Goodyear 5/20 (25%)  verum
 1/27 ( 3.%)
2 true symptoms on at least 2
consecutive days and no
more than one false symptom
during the 14 days of the
study period.
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Brien 14 /101(13.9%) verum
15/105 (14.3%) placebo
2 true symptoms on at least 2
consecutive days and no
more than one false symptom
during the 21  days of the
study period.
Proving reactions are usually defined in relation to the occurrence of a particular
number or pattern of symptoms which would be expected as pathogenetic effects
from the specific test medicine. For Goodyear (1998) the proportion of individuals
experiencing a proving reaction was their secondary outcome and was defined as
experiencing at least 2 true symptoms on at least 2 consecutive days and no more
than one false symptom during the 14 days of the study period. On this measure 5
from 20 participants in the Belladonna group proved, and 1 from 27 in the placebo
group. 1 of the participants in the Belladonna group withdrew but had already
provided data as the reason for the withdrawal was a strong proving reaction with 2
true symptoms and no false symptoms. It is unclear why the authors do not include
this result in their final analysis.Vickers and Van Haselen (2001), for whom this was
also the secondary outcome measure, found no significant differences between
groups for the number of participants meeting predefined criteria for a proving
reaction. They report two different figures in relation to proving reactions: the number
of episodes of true symptoms and then the number of responders
(participants experiencing a proving reaction). There were more episodes of true
symptoms in the placebo group but, according to their own definition ( a difference
score of more than 10 or more during the trial period) there were actually  4 provers
from 52  in the verum group and 1 from 52 in the placebo group. Brien (2003)
reported no significant group differences in proving rates. Rates in this trial were over
14/101 and 15/ 105 : proving rates of  14.3% and 13.9 respectively. were reported, a
mean difference of 0.4% ( -9.3,10.1)
The studies by Brien and Goodyear both used very similar definitions of a proving
reaction, and yet found very different outcomes. Whilst the sample size was much
smaller Vickers and Van Haselen found proving rates four times higher in the verum
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group. The proving rates in the Goodyear trial are also higher in the verum group,
whilst Brien found no difference between verum and placebo groups. A closer look at
the definitions of proving reactions suggests a possible explanation for some of this
heterogeneity. It is not reported who defined the symptoms which were true and false
for the medicine used in the trial, or what process was used to select these
symptoms. In both the Brien and the Goodyear trials the medicine was Belladonna
30C, yet looking at the true and false symptoms used to define proving reactions in
the two trials there is not a single symptom which is common to both.
Whilst there was therefore some clear heterogeneity  between the three studies from
which data relating to proving reactions were pooled, a statistical assessment of this
heterogeneity gave a value of 55% which is considered moderate. The trials of Brien,
Goodyear and Vickers and Van Haselen were measuring similar things with similar
enough outcomes measures that  it was therefore deemed appropriate to pool the
data. As heterogeneity was moderate analysis using both fixed and random effects
models was carried out and the results compared.
Figure 3.11  Meta analysis ( fixed effects model)  Participants showing a proving reaction.
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Study or Subgroup
Brien 2003 HPT5
Goodyear 1998 HPT6
Vickers Van Haselen HPT2
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.43, df = 2 (P = 0.11); I² = 55%
Test for overall effect: Z = 1.24 (P = 0.21)
Events
14
5
4
23
Total
101
20
52
173
Events
15
1
1
17
Total
105
27
52
184
Weight
89.0%
4.5%
6.5%
100.0%
M-H, Fixed, 95% CI
0.97 [0.44, 2.12]
8.67 [0.92, 81.34]
4.25 [0.46, 39.39]
1.52 [0.78, 2.96]
Verum Placebo Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours control Favours experimental
Figure 3.12 Meta analysis ( random effects model)  Participants showing a proving
reaction.
In summary, inconclusive findings were identified from the three trials of varying
sizes that looked at overall proving reactions. It is likely that this  heterogeneity is
related to the variations in outcome measures and to the idiosyncratic reactions of
individuals to homeopathic medicines. Pooling of data and meta-analysis
demonstrated no significant differences.  Hence it is difficult to conclude from this
measure whether there are any differences between homeopathic medicines and
placebo when given to healthy participants.
3.15.2 Symptoms typical of the test medicine
In total, available data from 9 of  the included studies indicates that 2093 symptoms
typical of the test medicine occurred in 242 participants  taking verum compared to
1353 symptoms in 258 participants taking placebo.
 Standardised Mean Differences, where reported in the following paragraphs, have
been calculated for this review using mean difference data provided in the reports of
the trials. In using this outcome measure authors are assessing differences between
those receiving placebo and those receiving homeopathic medicine in the
experience of symptoms which might be expected from that medicine.Walach (2001)
looked for  9 categories of symptoms which they deemed typical for the test
medicine – Belladonna. The only type of symptoms observed more frequently with
Belladonna than with either baseline or placebo were throat symptoms ( P=0.07).
The authors note that the few significant differences found across the different
categories were weak and were lost when corrected for the number of tests
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Study or Subgroup
Brien 2003 HPT5
Goodyear 1998 HPT6
Vickers Van Haselen HPT2
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.92; Chi² = 4.43, df = 2 (P = 0.11); I² = 55%
Test for overall effect: Z = 1.18 (P = 0.24)
Events
14
5
4
23
Total
101
20
52
173
Events
15
1
1
17
Total
105
27
52
184
Weight
50.6%
24.6%
24.8%
100.0%
M-H, Random, 95% CI
0.97 [0.44, 2.12]
8.67 [0.92, 81.34]
4.25 [0.46, 39.39]
2.39 [0.56, 10.23]
Verum Placebo Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours control Favours experimental
performed. Overall the SMD for the groups was 0.13 (CI -0.16,0.43). Vickers and
Van Haselen ( 2001) defined 5 symptoms as true of their test medicine and 5 as
false and developed a score for the difference between the two based on the number
of days on which true and false symptoms occurred. They subtracted the difference
score for the baseline period from the score for the trial period to arrive at their
primary outcome measure. There were no significant differences between groups on
this measure [ SMD 0.03 CI -0.36,0.41] . Goodyear (1998) had, as a primary
outcome, the difference in the number of true and false symptoms experienced by
those in the verum and placebo groups. The test medicine was again Belladonna in
this trial. No significant difference was found between  the two groups ( the authors
state that confidence intervals cannot be calculated because the distributions are
non normal). Walach (2004) report no significant differences between symptoms
typical and atypical of their test medicine, Cantharis [ SMD 0.34,CI -0.8,1.48].  
Signorini ( 2005) had, as a secondary outcome measure the number of symptoms
which were concordant with symptoms reported in a previous HPT of the same
medicine. They report that, from  the number of new or unusual symptoms recorded
in their trial of two different medicines and placebo, 30 symptoms from the group
taking the first medicine were concordant with a previous HPT of the same medicine
(45% of the total) , compared to 10% of the symptoms recorded by those taking a
different medicine 
 Walach (2008) reports two trials, the first of which compared Ozone to placebo and
the second of which compared both Ozone and Iridium to placebo. In the first trial
the average number of symptoms deemed typical for Ozone was 75 in the verum
group and 45 in the placebo group. However, no significant differences were
reported between verum and placebo groups in terms of symptoms deemed typical
of the test medicine [SMD 0.52, CI -0.47,1.51] In the second trial a highly significant
difference was found between verum and placebo groups in terms of symptoms
typical for Ozone [SMD 1.17 CI 0.29,2.05]. The difference between Iridium and
placebo was not significant [SMD -0.23 CI -1.02,0.55]. Mollinger (2009) reported
significant differences between symptoms typical of the two trial medicines across
the verum and placebo groups. The two verum groups experienced 5 and 6
symptoms deemed typical of the respective medicines, compared to almost zero
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typical symptoms in the placebo group.  The data necessary to calculate SMDs for
this trial has not been available.
Overall, three of the individual trials reported significant differences – Signorini
(2005) Walach (2008) and Mollinger (2009). Unfortunately data was not available
from two of these which was suitable for pooling
A lack of consensus in relation to which symptoms can be deemed typical or true of
a particular homeopathic medicine means that there may be  clinical heterogeneity
relating  to this  outcome measure. 
However, data was  pooled where possible  for this outcome – (symptoms deemed
typical of the test medicine)  and assessed statistically.Statistical heterogeneity was
actually relatively low ( I2 =29%) and a fixed effects model was therefore used to
compare outcomes.
Figure 3.13 Meta-analysis Symptoms typical of the test medicine
Only one of the small trials for which suitable data was available had reported a
significant result on this dimension and pooling of results clearly showed that there
was no significant difference between the verum and placebo groups on this
measure.
3.15.3  Differences between baseline and intervention phases. 
Most HPTs measure comparative outcomes across verum and placebo groups;
many also involve a baseline period. 7  of the reviewed trials measured differences
between baseline and intervention periods in relation to the numbers and pattern of
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Study or Subgroup
Vickers Van Haselen HPT2
Walach 2001
Walach 2004 HPT7
Walach 2008 HPT9A
Walach 2008 HPT9B
Walach 2008 HPT9B
Total (95% CI)
Heterogeneity: Chi² = 7.07, df = 5 (P = 0.22); I² = 29%
Test for overall effect: Z = 1.49 (P = 0.14)
Mean
-0.125
27.37
35.7
75.3
7.9
6.9
SD
3.47
24
14.3
66.1
7.6
4.9
Total
52
87
6
10
11
12
178
Mean
-0.221
24.17
28.6
45.1
1.5
8.6
SD
3.01
23.74
23.2
32.2
1.8
8.5
Total
52
87
6
7
13
13
178
Weight
29.7%
49.6%
3.4%
4.5%
5.7%
7.1%
100.0%
IV, Fixed, 95% CI
0.03 [-0.36, 0.41]
0.13 [-0.16, 0.43]
0.34 [-0.80, 1.48]
0.52 [-0.47, 1.51]
1.17 [0.29, 2.05]
-0.23 [-1.02, 0.55]
0.16 [-0.05, 0.37]
Verum Placebo Std. Mean Difference Std. Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours experimental Favours control
symptoms occurring. There were two distinct approaches to this, with some trials
providing placebo to all participants in this period and some using it as a pure
observation period. As discussed in chapter one, it is known that the number and
pattern of symptoms produced by placebo interventions and  the number of
background symptoms reported on a daily basis by healthy volunteers both vary
widely but can be large. Comparing the change in symptom pattern from a baseline
period  to a period of either verum or placebo intervention is therefore instructive. 
Table 3.14 Differences in symptoms reported between baseline run in phases and
intervention phases of trials.
Trial and nature of baseline
run in period
Measures Used Outcomes
Walach(2001)
Observation only
No of symptoms typical of
medicine. Differences
between baseline and trial
for both placebo and verum
groups
No significant difference
Baseline run in –
24.26(22.15)
Placebo:24.17(23.74)
Verum :  27.37(24.00)
Walach (2004)
Observation only
No of symptoms typical of
medicine. Differences
between baseline and trial
for both placebo and verum
groups
Significant difference
between baseline and
experimental period for all
symptoms ( p=0.03 for typical
sx and p=0.02 for atypical sx)
Signorini 
Observation only
Qualitative  comparisons
between baseline
(observation only) period and
trial period
Qualitative measures only
Walach (2008)
Observation only
No of symptoms typical of
medicine. Differences
between baseline and trial
for both placebo and verum
groups
Significant difference.
Baseline run in 21.1 (SD20.1)
Placebo: 45.1(SD32.2)
Verum:   75.3(SD66.1) 
Vickers Symptom score in placebo No significant differences-
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Placebo run in
run in phase subtracted from
symptom score in trial phase.
statistics for differences
between run in and
experimental phase not
reported
Brien
Placebo run in
Proving reactions.
Differences between
baseline and trial for both
placebo and verum groups
Placebo run in – 7.9% and
6.7%
Treatment phase – 13.9%
and 14.3%
Walach (2001) noted that theoretically one might expect the lowest frequency of
symptoms during baseline with no intervention, followed by placebo and then verum.
In their trial instead they frequently found unexpected patterns with certain symptoms
higher in the baseline period than in either placebo or verum groups. In that trial
there were no significant differences in relation to symptoms deemed typical for the
trial medicine between baseline, placebo and verum results. Walach in a later trial
(2004) noted a significant increase in both symptoms deemed typical of the trial
medicine and in atypical symptoms between the one week baseline and the two
week intervention period, for both placebo and verum and groups. Signorini (2005)
used a one week run in period as an observational period. Qualitative comparisons
were made between the diary reports of  patterns of symptoms in the intervention
and the baseline periods. In two trials reported by Walach (2008) there were obvious
differences between baseline and intervention. In the first trial the mean number of
symptoms deemed typical of the trial medicine was 21.1 (SD20.1) in the baseline
period, and 45.1(SD32.2) and 75.3(66.1) in the placebo and verum groups during the
intervention phase. These figures do not reach statistical significance. In the second
trial, two medicines were compared to placebo. The mean number of symptoms
typical for the first medicine (Ozone) was 0.9 (1.6) at baseline, and in the trial was
1.5(1.8) in the placebo group, 3.6(2.8) in the Iridium group and 7.9(7.6) in the Ozone
group. For the group taking the second medicine, the pattern is less clear. In fact one
of the statistically significant results that the authors note is the counter-intuitive
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finding that symptoms deemed typical of Iridium are higher in the baseline phase
than in the experimental phase ( p=0.037)
Vickers (2001) used a one week placebo run in and symptom scores during this
period were subtracted from symptom scores during the intervention phase to arrive
at the primary outcome – a score to determine whether a proving reaction had taken
place. Brien (2003) also used a one week placebo run in. They found no difference in
proving rates between the verum and the placebo group. They do not comment on
the differences between  the run in phase ( in which both groups received placebo)
and the intervention phase but the data clearly shows that proving rates were twice
as high in the intervention phase for both groups. ( 13.9 and 14.3% compared to
7.9% and 6.7%)
Where the data was available there were significant differences between the run in
period and the experimental period in 3 of the 5 trials. One of these involved a one
week placebo run in; the others were observation only periods. Such results suggest
that the symptoms which occur during an intervention phase ( both in placebo and
verum groups) are different from those which occur in run in periods. Such an
outcome is consistent with the idea that expectancy effects can be significant: when
people expect that they may receive an intervention they are more likely to display
symptoms. It could also be argued that the observation run in period could act as a
learning period in which people progressively become more aware of symptoms and
of what is required in terms of observing and reporting. If this were the case then
differences between baseline and intervention would be an artefact of learning
through time rather than a real difference relating to the intervention.
3.15.4 Symptoms in typical categories
As noted earlier, expert guidance on the conduct of HPTs has suggested that data
from such trials should be gathered in particular categories. Only one of the papers
reported measures of  the numbers and proportions of symptoms in each of these
categories. (Dominici 2006). Using data from two small trials they found that new
symptoms constituted 174 (46%)and 83 (44%)  in the verum groups against 35(34%)
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in the placebo group. The figures for exceptional symptoms were 49 (13%) and 29
(15.5%) against  2(1%). Cured symptoms were 11( 3%) and 9 (4.5%) against 7%.
(8%).The return of old symptoms were 75(20%) and 36 (19%) against 8 (7%).
Common symptoms provided  68(18%) and 32(17%) of the symptoms in the verum
groups and  55(51%) of those in the placebo group. The authors report chi square
bivariate analysis of the number of symptoms in each category in the three groups.
Differences were found at high levels of confidence (P <0.001). The same control
group was used as a comparator for the two separate trials reported.
Table 3.15 Proportions of symptoms occurring in different categories
Category Dominici 2006 HPT3A Dominici 2006 HPT3B
New symptoms V = 174 (46%)
C= 35(34%)
V = verum C = control
V= 83(44%)
C= 35 (34%)
Old symptoms V= 75(20%)
C= 8 (7%)
V= 36(19%)
C= 8(7%)
Cured V = 11 (3%)
C = 7 (8%)
V= 9 (4.5%)
C = 7(8%)
Exceptional V = 49(13%)
C = 2 ( 1%)
V = 29(15%)
C = 2 (1%)
Common V = 68(18%)
C = 55 (51%)
V = 32 (17%)
C = 55 ( 51%)
Signorini (2005) measured the number of phrases recorded by participants in diaries
which contained unusual or new symptoms and the return of old symptoms.
However, numerical data relating to these outcomes are not reported.
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Given the small number of participants in the Dominici trials ( n=21) and the lack of
any other trials reporting data on these outcomes, no conclusions can be drawn in
relation to this outcome.
3.15.5 Placebo/Nocebo.
Means and percentages for the individual trials are reported below.
Table 3.16 Mean no of symptoms in placebo groups and percentage of participants
in placebo groups reporting pathogenetic symptoms.
Trial Mean no of
symptoms reported
in placebo groups.
Trial Percentage of participants
in placebo group reporting
pathogenetic symptoms
Walach (2001) 24.17 Signorini
(2005)
25-30% - any pathogenetic
symptom
Dominici
(2005)
18 Fisher (2001)
Fisher (2001)
70% - symptoms compatible
with the trial medicine
40%- symptoms compatible
with the trial medicine
Walach (2004) 28.6
16.2
Vickers, van
Haselen (2001)
40% - 2 symptoms on 2
consecutive days
Signorini 4.5 ( new or unusual Brien (2003) 14.3% - symptoms compatible
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(2005) symptoms only) with the trial medicine
Walach (2008) 64
12
Goodyear
(1998)
66% - at least one symptom
Mollinger(2009) 11
Walach (2001) found a mean of 24.17 symptoms in participants receiving placebo
during the trial. In the trials by Dominici et al the mean was 18. Walach (2004)
reported mean numbers of symptoms typical and untypical for the trial medicine  in
the placebo group as 28.6 and 16.2. Signorini reported that 58 phrases containing
new or unusual symptoms were recorded by the placebo group – a mean of 4.5 per
person. Walach (2008) reported two trials, with mean numbers of symptoms in the
placebo groups at 64 and 12 respectively. Mollinger (2009) reported a mean of 11
symptoms in the placebo group.
Signorini and colleagues (2005) pointed to several distinct responses to placebo
intervention. They noted that 25-30% of participants developed apparent
pathogenetic symptoms and that this nocebo effect is similar to that described
elsewhere. Fisher (2001) in two trials recorded how many participants in placebo
groups reported symptoms that might be deemed compatible with the trial medicine
on a pathogenetic index. Rates were 70% and 40%. Vickers reported that 40% of
placebo participants reported symptoms that had been deemed true for the test
medicine.Brien (2003) reported proving reactions in 14.3% of the placebo group.
Such a reaction was defined as at least two true symptoms on consecutive days and
no more than one false symptom. Goodyear reported that 66% (18 from 27)
participants in the placebo group  recorded  at least one symptom.
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The discussion in chapter one highlighted the impact of expectancy and Hawthorne
effects on the reporting of symptoms. The results found in this review demonstrate a
very high level of placebo or nocebo effects. For the narrower set of symptoms which
may be classed as typical of the test medicine the percentage of participants in
placebo groups displaying these symptoms is very high.( up to 70% and otherwise
between 25 and 40%). Those displaying any symptoms were up to 66%. Some of
these symptoms may have been pre-existing symptoms since the definition of
healthy participant at entry was often loosely defined and did not preclude the
existence of some symptoms.
CHAPTER FOUR – DISCUSSION 
4.1 Summary of findings
Meta –analysis of pooled data found no significant quantitative difference between
homeopathic medicines and placebo medicines in terms of pathogenetic effects. 
4.2 Strengths and weaknesses of this review.
This study is the first to review HPT’s which meet modern standards for trial design
and methodological quality.  Including only such studies means that the results are
likely to be less biased. However, in terms of  homeopathic theory all of the studies
shared a weakness, in that none of them selected volunteers for sensitivity to the
medicine. Research into homeopathy must be robust and of high quality in terms of
adopting accepted standards of trial design. It must also adopt designs which are
appropriate to the intervention.  All of the homeopathic literature suggests that only a
minority of individuals will respond to a particular homeopathic medicine. This is true
both in clinical practice  and also in pathogenetic trials. The exact proportion of
individuals who will respond to a given medicine is unknown but from data included
in this review the level of proving reactions and pathogenetic effects is unlikely to
exceed 14% of any random sample of the population. Levels of nocebo effects in
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any random sample of the population are likely to be at least at the same level.
Therefore HPT’s which involve random samples of the population are unlikely to
show quantitative differences between placebo and intervention groups.
Several aspects of methodological quality can have a direct bearing on outcomes.
Reviews often use sensitivity analyses to re-assess statistical outcomes according to
the inclusion or exclusion of different studies. (Crowther and Cook 2007).For
example excluding studies which are of lower size, or which did not have clear
procedures for randomisation. Such analyses are also used to compare the effects
of imputing missing data. In this review there was insufficient data to perform such
sensitivity analyses. Most of the studies were of good quality in relation to the key
design features as discussed. However, the included trials varied in size and it is
known that trial size can be a key factor in terms of the ability to detect true
outcomes.Trials with insufficient participants will be underpowered to detect real
differences in outcomes ( type II errors) for example ( Freiman et al 1978)
9 of the 15 trials included in this review had less than 50 participants.
It is highly likely that language bias affects the outcomes of this review.The study
was limited to studies for which a full translation was available in English. It is known
that many studies in the field of complementary medicine are published in languages
other than English. Some 15 % of the papers identified by the search strategy were
not fully available in English and were excluded from this review. Whilst the effect of
including or excluding non English papers in systematic reviews is not fully clear
studies have shown that, for conventional medicine, non English language papers
generally show smaller effect sizes, but that non English papers relating to
complementary medicine show the opposite, with larger effect sizes. (Bartlett 2000). 
Publication bias is also likely to be a factor in this review. It is known that studies with
results that are significant, studies of high quality and  those that are large  and/or
well-funded  are more likely to be submitted and accepted for publication,  than
studies without such characteristics. (Song et al 2000). A recently published
Cochrane review noted that  trials with positive findings (defined either as those that
were statistically significant (P < 0.05), or those findings perceived to be important or
striking, or those indicating a positive direction of treatment effect), had nearly four
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times the odds of being published compared to findings that were not statistically
significant (P ≥ 0.05), or perceived as unimportant, or showing a negative or null
direction of treatment effect. Whilst publication bias is a real problem and it may be
present in up to 50% of meta-analyses (Sutton et al 2000) in most cases it does not
seem to affect  the conclusions of the reviews concerned (Sutton et al 2000)
One way in which publication bias is widely assessed is by the use of the funnel plot.
(Cullinan 2005).This is a graphical display which plots the effect size reported in
each individual trial against some measure of the size of the trial, such as the overall
sample size or the standard error. The plot is so named because the shape of the
plot should appear like a funnel if no publication bias exists. This is because trials of
smaller size, which are always more numerous, show a large variation in the
estimates of effect size that they report. This is because random variation has a
great deal more influence in small trials. At the narrower end of the funnel fewer trials
of larger size will show a narrower range of variation in effect size estimates.
Funnel plots are only useful where there is an adequate distribution of studies with
varying sample sizes. It is also an unwarranted assumption to conclude that
asymmetry in a funnel plot automatically means that there is publication since other
factors can also lead to such asymmetry, such as differences in the quality of similar
sized studies, clinical heterogeneity and chance. Given these limitations and the
small number of studies available for this review, it was deemed that a funnel plot
would not add any useful information to this review.
4.3 Meaning of this  review.
The outcomes are consistent with the hypothesis that homeopathic medicines do not
produce pathogenetic effects in healthy volunteers. An alternative explanation     for
the findings would be relate to the  hypothesis outlined in chapter one that
pathogenetic effects will only occur in a minority of  sensitive volunteers. Goodyear
(1998) started with the hypothesis that 10 to 20% of participants were likely to exhibit
proving reactions in HPT’s. Walach had previously reported proving rates of just 1%
(Walach 1994).Data analysed from the studies included in this review found proving
rates of 13% in verum groups and 9% in placebo groups. This hypothesis has been
part of homeopathic theory since its inception. Hahnemann, who first developed
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homeopathy suggested this in his book the Organon of Medicine which has
continued to be the most influential publication in homeopathic medicine since it was
first published in1810. He stated that strong medicines will bring about alterations in
health, even in robust people. He then suggested that weaker ones , on the other
hand, “ reveal their true action only when tested on delicate susceptible and
sensitive people who are free from disease”.           (Hahnemann 1921)
It is somewhat puzzling then that none of the trials which were otherwise of high
quality and met the criteria for inclusion in this review, used a design which allowed
for screening and selection of sensitive volunteers. Such a design  could involve a
two stage process. Stage one of the trial could be conducted with the aim of
determining which participants are sensitive to the particular medicine being tested.
Careful quantitative and qualitative analysis of apparent pathogenetic effects in stage
one would be carried out by persons not involved in the trial. Judgements could then
be made about which participants have displayed sensitivity to the medicine and real
pathogenetic effects. In stage two this group would be randomised to receive the
same medicine again or placebo.  Participants and supervisors would remain blinded
throughout both stages. A major disadvantage of this proposal is the kind of sample
size that might be required at the outset to produce enough participants of the
required sensitivity. If just 13% of participants demonstrate proving reactions, then a
sample almost eight times larger would be needed for stage one in order to produce
enough sensitive volunteers for a sample with enough power for stage two.
However, a small group in stage two who have been predetermined as sensitive to
verum are more likely to display effects that are significantly different from placebo
than a large group of participants who have been recruited randomly in relation to
sensitivity.
Studies described in the Background section reported rates of nocebo symptoms of
up to 40%. Studies included in this review found similar rates for a smaller set of only
those symptoms which might be linked to the medicine on trial, suggesting that rates
for nocebo symptoms overall would be higher.  It was noted in chapter one that
nocebo symptoms are related to expectations and also to a range of other factors
including gender. In HPTs the purpose is to generate pathogenetic symptoms and so
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a high level of expectation is created in participants. The majority of participants in
HPTs are female – in the studies included in this review the level was 68.5%. Both of
these features – high expectations and female gender – are likely to lead to a higher
level of nocebo symptoms being reported in these trials than in other trials.
Data from these studies do suggest that overall rates of nocebo symptoms in the
populations, settings and contexts which are typical of HPTs may be as high as 70%.
Nocebo symptoms which are similar  to the symptoms expected from a homeopathic
medicine seem to occur in 40% of participants, and nocebo symptoms
indistinguishable from a proving reaction in 14%.
If only one in eight participants typically show a proving reaction, then this is unlikely
to be distinguishable from the high levels of nocebo symptoms which occur in HPTs.
This data also suggests that HPT’s without placebo comparator groups and careful
selection of symptoms will report high percentages of symptoms which are caused
by factors other than the  pathogenetic effects of the specific medicine. Homeopaths
do often use careful qualitative analysis before using symptoms from HPT’s to guide
practice but it remains likely that many symptoms which are recorded in the literature
against specific medicines remain unreliable, since many of these attributions
originate from poor quality HPT’s without adequate controls.
4.4Unanswered questions and suggestions for future research
It remains unclear whether homeopathic medicines can produce pathogenetic
symptoms in healthy volunteers which are quantitatively different from placebo
effects.
Only a small fraction of studies which were located met the inclusion criteria – some
3%. This concurs with the findings of the review by Dantas et al (2005) of the quality
of HPT’s, which suggested that quality had improved in recent years, but remained
low in many trials. Those who plan and design HPT’s should follow both the
extensive guidance which is available in relation to RCT’s and that which is available
in relation to HPT’s.
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The most important aspects of these , in terms of reducing bias, and in terms of
increasing the likelihood of distinguishing genuine pathogenetic effects from placebo
effects and background noise would be:
 Randomisation, using explicit procedures
 Use of placebo comparator groups
 Blinding of participants and researchers and verification of blinding
 Dealing with loss to follow up and adverse events appropriately.
 Using validated outcomes measures
 Operationalising the definition of health which is used as a standard inclusion
criteria for HPTs. The use of the SF36 as Fisher used, or some other well
validated and widely used measure is suggested.
In order to determine whether homeopathic medicines  can produce symptoms
which are quantitatively different from placebo in healthy volunteers it is also
suggested that future HPTs adopt some kind of framework for selecting sensitive
volunteers.In relation to outcome measures, counting symptoms which have been
predefined as linked to the test medicine seems to be a frequently used strategy. It
has been noted that there are problems in relation to verification and agreement of
such symptoms. Two of the included studies  used homeopathic belladonna but
there was no overlap at all between the sets of symptoms which had been chosen as
typical for belladonna. This example highlights the need to validate and reach
consensus on such measures. It is suggested that a panel of materia medica experts
reach agreements. 
Vickers and Van Haselen concluded at the end of their study that closed
questionnaires listing a limited number of symptoms are not a useful mechanism for
investigating drug proving phenomenon because such phenomena are rare and
idiosyncratic. This is consistent with the ideas discussed  in chapter one.It could be
added that such methods also rely on accuracy and agreement in selecting the
closed list of symptoms, and that these have not been demonstrated in HPTs so far.
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If such verification of specific symptoms is problematic a more useful measure of
outcomes may be to compare symptoms which occur in particular categories which
are expected according to the theory of HPTs. This approach is recommended in
much of the guidance relating to HPTs ( e.g. Wieland 1997, Riley 1997, ECH 1995)
but was taken in only one of the papers included in this review ( Dominici 2006). The
results of the two small trials included in this paper were significant and it is
suggested that larger HPTs are conducted using similar outcome measures i.e.
those that assess symptoms in the generally categories which are utilised in
homeopathic practice to assess response to treatment.
In terms of general guidance the REDHOT guidelines (Reporting Data on homeopathic
Treatments (RedHot  ): A supplement to CONSORT, Dean et al 2006 )which were
specifically developed  to improve the conduct and reporting of trials in homeopathy
should be updated to include guidance specifically relating to the design, conduct
and reporting of HPTs.
Given the widespread use of homeopathy and the uncertainty that remains in
relation to HPTs there is a clear need to develop appropriate research methodologies
for HPT’s, to plan and carry out HPTs which can determine whether homeopathic
medicines can be distinguished from placebo in pathogenetic trials, and to conduct
HPT’s which can verify that information which has been used in practice from
unreliable HPTs.
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